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ABSTRACT
In drug discovery, demand for drug candidates with increased potency has led to
synthesis of lipophilic molecules to enhance their binding to target. This has resulted in approvals
of large number of drugs having poor biopharmaceutical properties. Aqueous solubility of drugs
can be increased by various techniques, the simple and most commonly employed technique is by
preparation of inclusion complex using cyclodextrins. The Sulfobutyl ether β-cyclodextrin (SBEβ-CD) was used to enhance the aqueous solubility of progesterone and silymarin.
Progesterone is a female sex hormone, and it is crucial to maintain a basal level of
10-20 ng/mL to treat luteal phase deficiency or estrogen dominance and to maintain normal
physiological functions of progesterone. The clinical trials of available oral progesterone products
have shown high interpatient and intrapatient variability, attributed to progesterone’s low aqueous
solubility and resulting in sub-optimal or excessive plasma levels. The solubility of progesterone
in water was enhanced by SBE-β-CD, progesterone in 100 mM SBE-β-CD was ~2000-fold more
soluble than its intrinsic solubility. The optimized SBE-β-CD formulation increased ex-vivo rat
intestinal permeation of progesterone and rat oral bioavailability of progesterone in SD rats
compared to progesterone API.
Silymarin is an extract of Milk Thistle, major constituents are taxifolin, silychristin,
silydianin, silybin A, silybin B, isosilybin A and isosilybin B. The in vitro, preclinical and clinical
studies have demonstrated silymarin possesses hepatoprotective, anticancer, hypocholesterolemic,
cardioprotective effect and dermatological beneficial effect (treatment of UV induced erythema,
ii

melanoma, non-melanoma skin cancer, rosacea, melasma, vitiligo and psoriasis) both individually
and collectively. Solubility enhancement of silymarin constituent is utmost important to increase
bioavailability and to improve drug developability property. The solubility of silymarin in water
was enhanced by SBE-β-CD by conventional and heating method, heating method was found to
be more efficient with less time consuming. The oral bioavailability and tissue exposure of
silymarin constituents were increased on oral administration of SBE-β-CD–silymarin complex
compared to silymarin suspension. To treat dermal ailments SBE-β-CD–silymarin cream was
developed and optimized to stabilize the cream and increase the skin penetration and permeation
of all silymarin constituents across the skin.
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CHAPTER 1
Introduction
In drug discovery, demand for drug candidates with increased potency has led to synthesis
of lipophilic molecules to enhance their binding to targets (1). This has resulted in approvals of
large number of drugs having poor biopharmaceutical properties. Approximately 90% of the drug
in developmental stages and over 40% of approved drugs have poor aqueous solubility (2). Drug
solubility in GI fluid and permeation across GI barrier are two crucial factors governing the oral
bioavailability of a drug, drugs as to be dissolved in GI fluid to permeate across the GI membrane
(3). Drugs with poor aqueous solubility are variably absorbed leading to erratic bioequivalence
(4). The Biopharmaceutical Classification System (BCS) categorizes drugs intended for oral
administration based on their solubility and permeability. The drugs are classified into four classes
class I (high solubility and permeability), class II (low solubility and low permeability), class III
(high solubility and low permeability) and class IV (low solubility and permeability) drugs (5).
Solubility enhancement of BCS class II drug is utmost important to increase bioavailability (4)
and to improve drug developability property(3).
The aqueous solubility of lipophilic drugs is increased by employing different techniques
like particle size reduction (micronization, nanosuspension), solid dispersion, super critical fluid
processing, salt formation, micellar solubilization, solubilizers, hydrotrophy and cyclodextrin
inclusion complex preparation (3). In recent years, β-cyclodextrins have been widely used for
increasing aqueous solubility of lipophilic drugs (6,7).
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Cyclodextrins are macrocyclic oligosaccharides which take on a well-defined shape
containing a lipophilic cavity and hydrophilic groups on the outer surface. The lipophilic cavity
can accommodate a lipophilic drug and because of the solubilizing capability of the hydrophilic
groups the cyclodextrin can significantly enhance the aqueous solubility of otherwise insoluble
drugs (1).
There are three main types of cyclodextrins categorized based on number of α-(1,4)-linked
glycosyl units. The α-cylodextrin, β-cyclodextrin (β-CD) and γ-cyclodextrin are composed of six,
seven and eight α-(1,4)-linked glycosyl units, respectively (8). β-CD is less toxic and have higher
aqueous solubility compared to α-cylodextrin and γ-cyclodextrin, respectively. β-CD bind to and
partially surround lipophilic drugs and hence increase their aqueous solubility. The native and
modified β-CD are most extensively used to enhance aqueous solubility of drugs. Whereas β-CD
itself is relatively poorly water soluble, the modified β-CD such as methyl-β-cyclodextrins (M-βCD), hydroxy-2-propyl-β-cyclodextrins (HP-β-CD) and sulfobutyl-ether-β-cyclodextrins (SBE-βCD, known as CaptisolTM) have very high solubility (7,8). β-CD and M-β-CD upon intravenous
dosing are reported to cause nephrotoxicity (8,9). Due to safety concerns, the use of M-β-CD
(<10%) is limited to nasal and pulmonary drug delivery systems. The NOEL (no observed adverse
effect levels) reported for HP-β-CD and SBE-β-CD on oral administration in rats are up to 500
and 3600 mg/kg/day, respectively (9,10). The NOAEL of SBE-β-CD in rats is 7.2 times greater
than NOAEL of HP-β-CD. Hence, SBE-β-CD effects on oral and dermal pharmacokinetics of BCS
class II drugs were evaluated.
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CHAPTER 2
Optimization of Sulfobutyl-Ether-β-Cyclodextrin Levels in Oral Formulations to
Enhance Progesterone Bioavailability
1. Introduction
Progesterone is a female sex hormone produced by the adrenal gland and corpus luteum
(during the luteal phase)(11). Luteal phase deficiency (LPD) is a state of deficient progesterone
levels in which the patient is unable to maintain and regulate a normal menstrual cycle, pregnancy
and embryogenesis (12). It is essential to maintain a basal level of 10-20 ng/mL (11) of
progesterone to treat LPD and estrogen dominance (12). Progesterone is prescribed for assisted
reproductive technology cycles (in vitro fertilization), to support implantation in early pregnancy,
to control anovulatory bleeding, to prevent recurrent pregnancy loss and for treatment of secondary
amenorrhea (13). Progesterone is also used in prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women on hormone replacement therapy receiving conjugated
estrogen tablets (14).
Progesterone is a BCS class II steroidal drug (6) with a reported aqueous solubility of 0.007
mg/mL and low oral bioavailability (13). Most marketed oral progesterone products are
micronized and suspended in peanut oil base (e.g., Prometrium®) to increase intestinal absorption,
and consequently bioavailability and efficacy (15). The clinical trials of Prometrium® showed
high interpatient and intrapatient variability in Cmax and AUC(0-10h), indicating variation in oral drug
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absorption resulting in sub-optimal or excessive plasma levels of progesterone (13). The most
common alternative for progesterone is synthetic progestins (medroxyprogesterone acetate), but
these are associated with adverse effects (like fluid retention, acne, rashes, weight gain and
depression) due to their affinity to bind glucocorticoid, androgen, and mineralocorticoid receptors
(16). An alternate approach to enhance the potential efficacy of progesterone with increased oral
bioavailability and having low interpatient and intrapatient variability is to develop a formulation
to enhance its aqueous solubility (13).
Native and modified β-cyclodextrins are most commonly used because of their large cavity
size compared to α-cyclodextrins, which enable them to bind to and partially surround lipophilic
drugs and hence increase their aqueous solubility. β-CD and M-β-CD upon intravenous dosing are
reported to cause nephrotoxicity(8,9). Due to safety concerns, the use of M-β-CD (<10%) is limited
to nasal and pulmonary drug delivery systems. The no observed adverse effect levels (NOAEL)
reported for HP-β-CD and SBE-β-CD on oral administration in rats are up to 500 and 3600
mg/kg/day, respectively(9,10). Hence, HP-β-CD and SBE-β-CD are the cyclodextrin derivatives
most extensively evaluated for solubility enhancement of active pharmaceutical ingredients for
oral administration.
There are previously reported phase solubility studies of progesterone in SBE-β-CD (17)
and HP-β-CD (17,18), in which the solubility of progesterone was found to be 9.9 and ~7 mg/mL
in 100 mM of SBE-β-CD and 60 mM of HP-β-CD, respectively (17). The studies on evaluating
the solubility/permeability interplay of progesterone with cyclodextrins have shown that higher
concentrations of HP-β-CD in the formulation decrease the permeability of progesterone across
Caco2 cell monolayers, in PAMPA, in the rat jejunal model (6) and in the single pass intestinal
perfusion rat model (19). Studies in rat intestine have shown that sodium taurocholate and lecithin
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displace progesterone from HP-β-CD–progesterone complexes (19). The present study is designed
to evaluate the influence of gastric fluid contents on the SBE-β-CD–progesterone complex and to
study the effect of SBE-β-CD levels on ex vivo rat intestinal permeability and rat oral
bioavailability of the lipophilic drug progesterone.
The SBE-β-CD–progesterone equilibrium complex mixtures were prepared and isolated,
and then characterized by differential scanning calorimetry (DSC), Fourier transform infrared
spectroscopy (FTIR), proton and carbon nuclear magnetic resonance (NMR) spectroscopy and
computational methods. The isolated SBE-β-CD–progesterone complex mixture solubility in
simulated gastrointestinal fluid and displacement of progesterone by bile salts in water were
evaluated. The optimal levels of SBE-β-CD required to prevent displacement of progesterone by
the contents present in fasted state simulated intestinal fluid (FASSIF) and fed state simulated
intestinal fluid (FESSIF) were determined by employing a simple in vitro experiment. Ex vivo
permeation studies were performed to evaluate permeation of progesterone across rat intestine and
the effect of excess SBE-β-CD on the permeation. The oral bioavailability of progesterone, the
isolated SBE-β-CD–progesterone complex mixture, and the isolated SBE-β-CD–progesterone
complex mixture with excess SBE-β-CD was evaluated in Sprague Dawley rats. To evaluate the
potential utility of this isolated SBE-β-CD–progesterone complex mixture in human, in vitro
dissolution of progesterone API and the isolated SBE-β-CD–progesterone complex mixture filled
into capsules were evaluated in water, simulated gastric fluid (SGF) and simulated intestinal fluid
(SIF).
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2. Materials and Methods
2.1 Chemicals and reagents
Progesterone, pepsin, phosphate buffered saline and L-α-phosphatidylcholine (lecithin)
were purchased from Sigma Aldrich, Inc., USA. SBE-β-CD (Captisol®) was provided by Ligand
Pharmaceuticals, Inc, USA, who in part funded the study. Sodium taurocholate was purchased
from Alfa Aesar, USA. Euthasol® (pentobarbital sodium and phenytoin sodium) solution was
procured from Virbac, USA. Methocel E15 Premium EL (hydroxypropyl methyl cellulose) was
purchased from the Dow Chemical company, USA. The HPLC grade solvents acetonitrile,
methanol, dibasic potassium phosphate, dibasic sodium phosphate, glacial acetic acid,
hydrochloric acid, sodium hydroxide, sodium chloride, sodium acetate, ortho-phosphoric acid and
Milli Q water were of research grade and were used without further purification.

2.2 Phase solubility studies
The solubility enhancement of progesterone by complexation with SBE-β-CD was
evaluated by adding excess amounts of progesterone to different concentrations of SBE-β-CD (10,
20, 40, 60, 80 and 100 mM) in Milli-Q® water (Higuchi and Connors method) (20). Samples were
kept shaking at 25 °C for 3 days and at equilibrium samples were filtered using a Millipore (0.45
μm) syringe filter. The filtrate was analyzed using HPLC to evaluate the saturation solubility of
progesterone in SBE-β-CD. Phase solubility study curves were used to calculate complexation
efficiency (CE) and stability constants (K1:1).
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2.3 Characterization of the isolated SBE-β-CD–progesterone equilibrium complex mixture
The complex was prepared by adding excess progesterone (~35 to 40 mg/mL) to 100 mM
SBE-β-CD in Milli-Q® water. Samples were kept shaking at 25 °C for 3 days and at equilibrium
samples were filtered using a Millipore (0.45 μm) syringe filter. These samples were lyophilized
and characterized using DSC, FTIR and NMR. The complex was also studied by computational
methods.

2.3.1 Differential scanning calorimetry
The isolated SBE-β-CD–progesterone complex mixtures were characterized with a DSC
25 Series, TA instrument equipped with Pyris software (Shelton, CT, USA). Approximately 3-3.5
mg of progesterone API, of a physical mixture of SBE-β-CD and progesterone, and of the
lyophilized complex mixture were hermetically sealed in a crimped aluminum pan and heated from
25 °C to ~200 °C, at a heating rate of 10 °C/min to obtain a DSC thermogram.

2.3.2 Fourier transform infrared spectroscopy
FTIR studies were conducted on an Agilent Technologies Cary 660 (Santa Clara, CA.).
The bench was equipped with an ATR (Attenuated Total Reflectance MIRacleTM, Pike
Technologies, Madison, WI) which was equipped with a single bounce diamond coated ZnSe
internal reflection element. FTIR spectroscopic analysis was performed on the prepared complex
by scanning over the range from 400 to 4000 cm-1 (21).
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2.3.3 Nuclear Magnetic Resonance studies
The 1H-NMR spectrum of progesterone, the isolated SBE-β-CD–progesterone complex
mixture, the physical mixture of SBE-β-CD and progesterone, and pure SBE-β-CD dissolved in
DMSO-d6:D2O (2:1) were recorded on a Bruker Advance DRX 500 MHz FT NMR instrument at
298 K. The
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C NMR spectra of progesterone and of the isolated SBE-β-CD–progesterone

complex mixture dissolved in DMSO-d6 were also obtained. The spectra were processed with
software Topspin 3.2.

2.3.4 Molecular modeling
The computational study utilized the Maestro 10.5 program from the Schrödinger Software
Suite. The 3D X-ray structure of -CD was retrieved from the Protein Data Bank (PDB ID:1JL8)
(22), and was modified to produce four models of cyclodextrin isomers for SBE-β-CD, in an
approach similar to that reported by Jain et al. (2011) (23) to represent the possible structural
arrangements of sulfobutyl ether groups in the SBE-β-CD structure (Fig. 1). Isomer 1 was prepared
by placing all of its sulfobutyl ether groups on the positions of primary hydroxyl groups (6-OH on
the glucose subunits) of β-CD whereas Isomers 2 and 3 were prepared by attaching three sulfobutyl
ether groups to primary hydroxyl groups and four to secondary hydroxyl groups (2-OH on the
glucose subunits) of β-CD. The final Isomer 4 was constructed by placing one sulfobutyl ether
group on a primary hydroxyl group (6-OH), three on secondary 2-OH hydroxyl groups, and three
on secondary 3-OH hydroxyl groups (3-OH) on the glucose subunits of β-CD. This isomer is
representative of a general overall distribution found for Captisol (22). The sulfobutyl group was
used in its ionized form. We followed similar procedures for conformational search and for
docking as reported in our previous publication (23). A conformational search of modified SBE-
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β-CD (for all four isomers) was done separately using MacroModel’s Macrocycle Conformational
Sampling (MCS) (24) tool (Schrödinger), employing the OPLS2005 force field. During the MCS,
the large-scale low-mode (LLMOD) method was used with the generalized Born model [GB/SA]
solvent treatment. Redundant conformers were eliminated using an RMSD cutoff of 0.75 Å. The
energy window for saving structures was set to 10 kcal/mol and the enhanced torsional sampling
option was used. The resulting conformers were minimized in the gas phase using the PolakRibière Conjugate Gradient (PRCG) method with the OPLS2005 force field. Progesterone was
sketched in Maestro (25) and energy-minimized using the LigPrep (26) module of Schrödinger,
using the OPLS2005 force field at pH 7.4. Those conformers within an energy window of 7.5
kcal/mol were selected for docking of progesterone, which was done using Glide (Schrödinger)
(27), with Standard Precision and flexible ligand sampling. Docking grids were prepared for each
conformer of each SBE-β-CD model in such a manner as to ensure that the whole SBE-β-CD
structure was labeled as the active site. The binding free energies were calculated on the
representative complex after MD simulation using Prime MM-GBSA (28) considering refinement
of polar hydrogens only, applying the variable dielectric generalized Born (VSGB) water model.
The 2D structures of SBE-β-CD isomers and progesterone are shown in Figs. 1 and 2, respectively.
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Figure 1. 2D structures of the four different isomeric forms of SBE-β-CD used for computational
study.
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Figure 2. 2D structure of progesterone with atom and ring numbering.

2.3.5 Molecular dynamics simulations
MD simulations for the best complexes of progesterone and SBE-β-CD were carried
out using the Desmond (29,30) program. The best complex of each isomer with progesterone
(SBE-β-CD–progesterone complex) was solvated with TIP3P (31) waters in a cubic box of side
length 10 Å with periodic boundary conditions. The solvated complex was neutralized by adding
7 Na+ ions, yielding a salt concentration (NaCl) of 0.15 M. The constructed system was simulated
with the modified NPT relaxation protocol in Desmond. The protocol involved an initial
minimization of the solvent while keeping restraints on the solute, followed by short MD
simulations of 12–24 ps in sequential NVT and NPT ensembles with the Langevin thermostat and
barostat, respectively. The temperature was maintained at 300 K throughout the production run
using the Langevin algorithm and the pressure was isotropically restrained to 1 bar with the
Langevin barostat (32). The short-range Coulombic interactions were set to a cut-off value of 9.0
Å using the short-range method, while the smooth particle mesh Ewald method was used for
handling long-range Coulombic interactions. After completion of the relaxation protocol, the final
production run of 5 ns was carried out on the solvated complex, to avoid any structural artifacts
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introduced during system buildup and equilibrium steps. During the simulation, the trajectories
were sampled at an interval of 4.8 ps. The structural stability of the complexes was analyzed based
on the root-mean-square deviation (RMSD), for which the first frame was used as a reference. The
number of intermolecular hydrogen bonds between progesterone and SBE-β-CD was also
calculated. Representative complexes were subjected to binding free-energy calculations using
Prime MM-GBSA.

2.4 Solubility of progesterone and SBE-β-CD-progesterone complex
The solubility studies were performed in water, fasted state simulated gastric fluid
(FASSGF) at pH 1.6, fed state simulated gastric fluid (FESSGF) at pH 5.0, FASSIF at pH 6.5 and
FESSIF at pH 5.8. The above mentioned gastrointestinal simulated fluids were prepared using
previously published protocols (33). The solubility was evaluated by adding excess progesterone
API and 25 mg of isolated SBE-β-CD–progesterone complex mixture in water and simulated
gastrointestinal fluids. Samples were kept shaking at 37 °C for 8 h at 100 rpm in a Bio-shaker and
samples were filtered using a Millipore (0.45 μm) syringe filter. The filtrate was analyzed using
HPLC to evaluate the solubility of progesterone. Note: the filter was determined not to interfere in
the determination.

2.5 Effect of sodium taurocholate on SBE-β-CD–progesterone complex
The effect of sodium taurocholate on the solubility of the isolated SBE-β-CD–progesterone
complex mixture was evaluated by adding 25 mg of lyophilized complex to different
concentrations (2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30, 40 and 50 mM) of sodium taurocholate. The
above samples were kept shaking at 37 °C for 8 h at 100 rpm in a Bio-shaker and samples were
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filtered using a Millipore (0.45 μm) syringe filter. The filtrate was analyzed using HPLC to
evaluate the solubility of progesterone in the presence of sodium taurocholate.

2.6 Effect of excess SBE-β-CD on sodium taurocholate displacement of progesterone from
SBE-β-CD–progesterone complex
The effect of excess SBE-β-CD on sodium taurocholate displacement of progesterone from
the isolated SBE-β-CD–progesterone complex mixture was evaluated by adding 25 mg of
lyophilized complex to different concentrations (0, 5, 10, 20, 30, 40 and 50 mM) of SBE-β-CD in
a solution containing 20 mM sodium taurocholate. The above samples were kept shaking at 37 °C
for 8 h at 100 rpm in a Bio-shaker and samples were filtered using a Millipore (0.45 μm) syringe
filter. The filtrate was analyzed using HPLC to evaluate the solubility of progesterone in the
presence of excess SBE-β-CD and sodium taurocholate.

2.7 In vitro simulation to evaluate effect of excess SBE-β-CD on displacement of progesterone
from SBE-β-CD–progesterone complex in FASSIF and FESSIF
The effect of excess SBE-β-CD on the solubility of the SBE-β-CD–progesterone complex
in FASSIF and FESSIF was simulated in vitro. 25 mg of the lyophilized complex and different
concentrations of excess SBE-β-CD were added to FESSIF (2.5, 5, 7.5,10, 15 and 20 mM of SBEβ-CD) and FASSIF (1, 2, 3, 4, 5, 7.5 and 10 mM of SBE-β-CD), respectively. The above samples
were kept shaking at 37 °C for 8 h at 100 rpm in a Bio-shaker and samples were filtered using a
Millipore (0.45 μm) syringe filter. The filtrate was analyzed using HPLC after appropriate dilution
to evaluate quantities of solubilized progesterone in samples.
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2.8 Stability studies
Lyophilized powder was packed in screw capped HDPE bottles and liquid equilibrium
complex mixture were packed in glass vials and stored in a stability chamber under two conditions,
at 40 °C and 75% RH and at 25 °C and 60% RH. The stability was assessed by evaluating drug
content in samples after 3 and 6 months using HPLC.

2.9 Animal studies
The animal studies were conducted at University of Mississippi, School of Pharmacy, as
per the protocol #14-021, approved by the Institutional Animal Care and Use Committee and
Animal Welfare Assurance # A3356-01. On arrival, rats were housed in cages at the Animal Care
Facility in a temperature and humidity controlled room with a 12:12 h light:dark cycle, and they
were provided free access to food and water for one week before use in the experiments.

2.9.1 Ex vivo rat intestinal permeation studies
Three male rats (225-250 g) fasted overnight the day before the experiment but had free
access to water. On the day of the experiment, the rats were removed from the animal care facility
and brought to the procedure lab. The rats were euthanized using an intraperitoneal (i.p.) dose of
Euthasol® (150 mg/kg body weight). The abdomen was cut open using an incision of 4-5 cm and
the proximal small intestine segment was isolated. The isolated small intestine was slowly flushed
with phosphate buffered saline (PBS) at pH 7.4 to remove the intestinal content. The freshly
harvested small intestine was cut open to expose the mucosal layer and cleaned by a gentle flow
of PBS at pH 7.4 on the mucous surface. Fresh rat intestine was sandwiched between two chambers
of a Franz diffusion cell with an active diffusion area of 0.64 cm2, and the mucosal layer was
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exposed to the donor chambers. The resistance across rat intestine was measured using a wave
form generator to ensure the integrity of the small intestine segment used for the permeation study.
Rat intestine with resistance of ≥3 KΩ.cm2 was used for permeation studies. To the donor
compartment, 500 µL of complex dissolved in water (200 µg), FASSIF (203 µg), FESSIF (213
µg), FASSIF (219 µg) (with excess 5 mM SBE-β-CD), FESSIF 228 µg (with excess 15 mM SBEβ-CD) and the positive control (51 µg) of progesterone dissolved in 0.5% of Brij S20 were used
for permeation studies. The receiver chamber was filled with 5 ml of 0.5% of Brij S20, which was
stirred at 600 rpm with a 3 mm magnetic stir bar and the temperature was maintained at 37 °C with
a circulating water bath. 200 μL samples were withdrawn from the receiver compartment at
different time intervals (0, 0.25, 0.5, 1, 2, 4, 6 and 8 h) and each time an equal volume of fresh
receiver media was used to replace what was withdrawn. The above samples were transferred into
vials and subjected to HPLC analysis.

2.9.2 In vivo pharmacokinetic studies
The 16 jugular vein cannulated male rats were used for pharmacokinetic studies. These
animals fasted overnight and had free access to water on the day before the experiment. On the
day of the experiment, the rats were removed from the animal care facility and brought to the
procedure lab. Animals were randomly divided into four different groups of 4 animals each (Group
I: PO isolated SBE-β-CD–progesterone complex mixture; Group II: PO progesterone API; Group
III: PO isolated SBE-β-CD–progesterone complex mixture with excess SBE-β-CD; and Group IV:
progesterone IV). Each oral dose was weighed and filled in Tropac® Capsule 9el (gelatin). The
capsules to animals of Groups I, II and III were administered by placing the capsule in the Torpac®
capsule gavage needle attached to a dosing syringe. The delivery tube of the dosing syringe was
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placed in the mouth and advanced along the lower palate as far as the esophagus for administration.
After administration of capsules, 1 mL of water was administered to Group I and II animals, and
to Group III animals 1 mL of water containing 15 mM of SBE-β-CD was administered. The dose
to Group IV was administered by slow bolus intravenous injection into the tail vein (dosing
volume: 2 mL/kg body weight). Approximately 200 µL of blood was drawn into heparin-coated
tubes at pre-dose, 0.08, 0.17, 0.33, 0.5, 0.75, 1, 1.5 and 2 h through jugular vein catheter. Plasma
was harvested by centrifuging the blood at 4000 rpm for 5 min and stored frozen at 80 ± 10 °C
until analysis.

2.10 In vitro dissolution studies
The dissolution studies were carried out for progesterone API and the isolated SBE-β-CD–
progesterone complex mixture filled in capsules containing the dose equivalent to 100 mg of
progesterone. The drug profile was evaluated using a USP dissolution apparatus-I (Hanson SR8,
Chatsworth, CA) maintained at 37 ± 0.5 °C and having a shaft rotation speed of 100 rpm. The
dissolution test was performed using 900 mL of water, simulated gastric fluid (pH 1.2) and
simulated intestinal fluid phosphate buffer (pH 6.8). The samples were withdrawn at 5, 10, 15, 20,
30, 45, 60, 90 and 120 min intervals and the filtrate was analyzed using HPLC after appropriate
dilution. The in vitro dissolution profile was used to calculate dissolution parameters including
mean dissolution time (MDT), mean dissolution rate (MDR) and initial dissolution rate (IDR) (34).

2.11 HPLC analysis
The HPLC method was developed using a Shimadzu UFLC system, equipped with prominence
SPD-M20A (Diode array detector). The chromatographic separation of progesterone and the
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internal standard (IS) (fenofibrate) was achieved on a Waters XTerra® RP18 5 µm column with
dimensions 4.6 mm x 150 mm, which was maintained at ambient room temperature. The binary
mobile phase system consisted of methanol:0.1% formic acid in water [80:20 v/v] at a flow rate of
1.2 mL/min. All solubility, in vitro and ex vivo samples were subjected to HPLC analysis without
any further extraction procedure.

2.11.1 In vivo sample preparation
A simple protein precipitation method was followed for extraction of progesterone from in
vivo study samples. To an aliquot of 50 µL of rat plasma sample, an internal standard solution (5
µL of fenofibrate 5 µg/mL) was added and the mixture was vortexed, after which 200 µL of
acidified acetonitrile was added and the mixture was again vortexed. The sample was centrifuged
at 4 °C for 10 min at 14,000 rpm on a Centrifuge 5430R (Eppendorf, Germany) and the supernatant
was transferred to a vial for HPLC analysis. The UV detection wavelength was 242 nm. The
compound eluted at 3.9 min and the internal standard eluted at 5.5 min with a total run time of 8
min.

3. Results and Discussion
Progesterone is a BCS Class II drug (6), and hence its oral absorption is limited due to low
aqueous solubility. It is crucial to enhance the solubility/dissolution of the drug to overcome its
poor and variable bioavailability issues.
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3.1 Phase solubility
The phase solubility curve (Fig. 3) demonstrates a linear solubility increase of progesterone
as a function of increase in concentration of SBE-β-CD, indicating an AL type curve (35). The
aqueous solubility of progesterone increased 1972 ± 77.8-fold in the presence of 100 mM of SBEβ-CD compared to the intrinsic solubility of progesterone in water (Table 1). The affinity (stability)
constants (K1:1) Eq. (1) and complexation efficiencies (CE) Eq. (2) of SBE-β-CD–progesterone
were calculated based on the parameters of the phase solubility plot.
Equation 1. Stability constant (K1:1)
𝒎
(𝟏−𝒎)
𝟎

𝑲𝟏:𝟏 = 𝑺

Equation 2. Complexation efficiency (CE)
𝒎

𝑪𝑬 = (𝟏−𝒎)
where m is the slope of the curve obtained by plotting the drug solubility versus
cyclodextrin concentration, determined by linear regression. The CE and K1:1 of the SBE--CD–
progesterone complex were 1.65 ± 0.21 and 52,670 ± 4914 M-1, respectively, considering the
intrinsic solubility (0.031 mM) for the stability constant calculation. By contrast, the stability
constant was determined to be 983 ± 320 M-1, based on the intercept. This huge variation of
stability constant could be due to the non-ideality of water as solvent. Poorly soluble drugs show
a negative intercept deviation, i.e., Sint (intercept of phase solubility curve) < S0 (drug solubility in
deionized water), which leads to overestimation of K1:1 when determined from the slope and
intercept (18).
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Figure 3. Phase solubility profile of progesterone in SBE-β-CD (R2 = 0.9986).
Table 1. Progesterone solubility enhancement by SBE-β-CD. Each point represents mean ± SD of
triplicate values.
SBE-β-CD (mM)

Progesterone (mM ± S.D.)

Number of fold increase in
solubility

0

0.03 ± 0.001

1.00 ± 0.00

10

5.08 ± 0.11

161 ± 3.47

20

11.3 ± 0.20

358 ± 6.33

30

16.4 ± 0.76

522 ± 24.1

40

22.2 ± 0.93

734 ± 29.7

50

28.4 ± 2.04

904 ± 64.7

100

61.0 ± 2.45

1972 ± 77.8
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3.2 Characterization of SBE-β-CD–progesterone complex
3.2.1 Differential scanning calorimetry
DSC thermograms of progesterone, SBE-β-CD, physical mixtures of progesterone with
SBE-β-CD and the SBE--CD–progesterone complex are represented in Fig. 4. SBE-β-CD
demonstrates no crystallinity. Progesterone API exhibited a sharp melting endotherm at 132 °C
confirming its inherent crystalline property. The endothermic peak (melting peak) of progesterone
was reduced in the physical mixture but completely disappeared in the complex, indicating
interactions between drug and cyclodextrin resulting in the loss of crystallinity (36,37) of
progesterone.

Figure 4. DSC thermograms of SBE-β-CD–progesterone complex, SBE-β-CD, physical mixture
and progesterone API.
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3.2.2 Fourier Transform Infrared (FTIR) spectroscopy
FTIR has been extensively used to analyze the interaction between cyclodextrins and guest
molecules in the solid state. In general, the spectra of inclusion complexes exhibit significant
broadening of bands, indicating the formation of inclusion complexes. The FTIR bands of
progesterone that correspond to ketone stretches at 1697 (at C3 position) and 1660 (at C20
position) cm-1 were disappeared and broadened, respectively in the SBE--CD–progesterone
complex (Fig. 5). The disappearance of the ketone stretching bands at 1697 may indicate formation
of inclusion complexes in which a C3 position participates in a hydrogen bond between SBE-βCD and progesterone. There were no other significant changes observed in the spectral pattern of
SBE--CD or progesterone compared to the complex, signifying that there were no other chemical
changes involved in the formation of the inclusion complex.
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Figure 5. FTIR spectra of SBE--CD (CaptisolTM), progesterone, SBE--CD–progesterone
physical mixture and SBE--CD–progesterone complex.
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3.2.3 NMR studies
The 1H NMR spectra of progesterone, SBE-β-CD and its complexes (physical and
inclusion complexes) were recorded to gain deeper insight into the interaction of the drug with
cyclodextrin. The 1H NMR spectra of progesterone and the SBE-β-CD–progesterone complex with
important protons (most affected by complexation) of progesterone are shown in Fig. 6. The 13C
NMR spectra of progesterone and the SBE-β-CD–progesterone complex with important carbons
of progesterone are shown in Fig. 7. The chemical shifts observed for progesterone are given in
Tables 2 and 3.

3.2.3.1 Proton (1H) and carbon (13C) nuclear magnetic resonance
1

H and

13

C NMR are effective tools that can be used to confirm complexation and also

provide insight into the mode of inclusion of a guest into the host cavity. The changes in the
chemical shift patterns of the complex, relative to those for the isolated drug, are indicative of
host–guest interaction. Selected proton signals of progesterone and the SBE--CD–progesterone
complex in DMSO-d6:D2O are summarized in Table 2. Similarly, selected carbon data of
progesterone and its inclusion complex are shown in Table 3. Due to the structural complexity of
SBE--CD, it was difficult to assign the protons and carbons of the cyclodextrin itself by 1H and
13

C NMR; therefore, we only monitored the changes in the spectrum of progesterone in the

inclusion complex. The differences found in the chemical shifts of progesterone in the SBE-CD–progesterone complex indicate that Ring A and Ring D of progesterone each have the
possibility to be included within the SBE--CD cavity.
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Table 2. Selected 1H NMR chemical shifts of progesterone and the SBE7--CD–progesterone
complex.
Progesterone protons

Free progesterone

SBE--CD–progesterone

Difference

(atom numbering)

(ppm)

complex (ppm)

(ppm)

H4

6.02

6.11

0.09

H17

2.61

2.67

0.06

H18

0.91

1.01

0.10

H21

2.45

2.37

−0.08
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A

B

Figure 6. 1H NMR spectra of (A) progesterone and (B) SBE-β-CD–progesterone complex in
DMSO-d6-D2O (2:1).
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Table 3. Selected 13C chemical shifts of progesterone and the SBE--CD–progesterone complex

Progesterone protons

Free progesterone

SBE--CD–progesterone

Difference

(atom numbering)

(ppm)

complex (ppm)

(ppm)

C3

197.912

198.246

0.334

C4

123.187

123.271

0.084

C5

170.727

171.090

0.363

C17

62.468

62.577

0.109

C20

208.398

208.727

0.329

C21

31.144

31.292

0.148
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A

B

Figure 7.

13

C NMR spectra of (A) progesterone and (B) SBE-β-CD–progesterone complex in

DMSO-d6-D2O (2:1).
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3.2.4 Molecular modeling
3.2.4.1 Conformational search
A total of 968, 970, 971 and 669 conformers of SBE--CD were generated using the MCS
tool within a cutoff window of 10 kcal/mol, for Isomers 1, 2, 3, and 4, respectively. We selected
10, 8, 15, and 10 conformers for Isomers 1, 2, 3, and 4 respectively, which matched the criteria of
having a slightly open cavity (suitable for docking).

3.2.4.2 Docking and molecular dynamics of SBE--CD–progesterone complex
The progesterone molecule was docked into the four isomers of SBE--CD using the Glide
standard precision (SP) method implemented in the Schrödinger software with flexible ligand
sampling. The docking and scoring of progesterone into the generated grids of each low energy
conformer of each isomer resulted in the most favorable SBE--CD–progesterone complexes
(Table 4). The best docking complex of each isomer was subjected to a 5 ns MD simulation to
help understand the stability and binding orientation of the complexes.
The representative complexes of progesterone with the four different SBE-β-CD isomers
from the MD simulations are shown in Fig. 8. Since the H4 and H21 protons (located on opposite
ends of progesterone) in the 1H NMR of progesterone (Fig. 6, Table 2) were downshifted and
upshifted, respectively, in the SBE--CD–progesterone complex, we interpreted that to show that
progesterone forms inclusion complexes with SBE--CD in two different orientations (pose A:
C3, and pose B:C20 carbonyl facing the hydroxyl of SBE-β-CD). To get more insight into the
structure of the inclusion complexes, we also performed 13C NMR for SBE--CD–progesterone.
The chemical shifts of progesterone at C3, C5, C17, C20, and C21 showed significant changes
after formation of the inclusion complex with SBE-β-CD. These data further supported that
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progesterone interacts with SBE-β-CD in two different orientations. In our MD simulations we
explored both such orientations. In Fig. 8, progesterone was seen to interact with SBE-β-CD on
the secondary face in all of the isomers, using the starting point as Pose A, in which the carbonyl
at C3 of Ring A formed an H-bond with the hydroxyl of SBE-β-CD (Fig. 8). Meanwhile we ran
alternate MD simulations starting with the alternative pose (Pose B) of progesterone having the
C20 carbonyl of progesterone H-bonded with the hydroxyl of SBE-β-CD for Isomers 1 and 4
(Table 4 and Fig. 9) and that stable pose was well maintained during the simulation. The pose B
for isomer 2 and 3 was not considered for molecular dynamics simulation, due to very poor
docking scores and orientation/pose of progesterone was not found inside the cavity of SBE-7CD. The details of the interactions between progesterone and the protein in the different
simulations clearly illustrate how the change occurs in the pattern of the NMR signals of the
protons (H4 and H21) and carbons (C3, C20) of progesterone (Figs. 6 and 7) in the progesterone–
SBE-β-CD complex. The binding free energies from the MD simulations (Table 4) revealed that
there is a more favorable interaction of progesterone with SBE-β-CD when the C3 carbonyl group
of Ring A is embedded in the cavity of SBE-β-CD (Pose A). Overall, all four possible isomers of
SBE-β-CD showed H-bonds with progesterone at the C3 or at the C20 carbonyl group with
progesterone partially embedded in the SBE-β-CD cavity, and thus either Ring A or Ring D lies
within the SBE-β-CD cavity. This matches well with the experimental (1H NMR and 13C NMR)
data (Figs. 6 and 7, and Tables 2 and 3) and helps to confirm the formation of the inclusion complex
of progesterone with SBE-β-CD.
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A
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D

E

F

G

H

Figure 8. Binding poses (Pose A) after 5 ns molecular dynamics simulations of representative
complexes of progesterone (ball and stick model) with Isomer 1 (A and B); Isomer 2 (C and D);
Isomer 3 (E and F) and Isomer 4 (G and H) of SBE-β-CD (line representation, left images; CPK
model, right images). Hydrogen bonds are shown in yellow dashes.
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A

B

C

D

Figure 9. Binding pose (Pose B) of a representative complex of progesterone (ball and stick model)
with Isomer 1 (A and B) and Isomer 4 (C and D) of SBE-β-CD (line representation, left images;
CPK model, right images). A hydrogen bond is shown with yellow dashes.

30

Table 4. The energetic profile of the most favorable inclusion complexes of progesterone with SBE--CD models (Captisol®) before
molecular dynamics simulations, in Pose A (Ring A downward) or Pose B (Ring A upward) and computed Binding Free Energies for
the four SBE-β-CD–Progesterone Complexes after MD Simulations.
SBE--CD–progesterone complex
Complex
Pose A
Isomer

1

2

3

4

1

4

Conformer Number

8

5

5

1

2

3

Docking Score (kcal/mol)

–4.384

–4.422

–5.187

–5.288

–3.805

–4.936

Emodel

–30.476

–28.836

–36.023

–41.387

–26.338

–37.661

ΔG (kcal/mol)

–51.410

–40.136

–45.544

–57.930

–48.632

–45.860
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Pose B

The Pose A MD trajectories revealed persistent intermolecular hydrogen bonds (Fig. 10 and
Supplementary Fig. S1) between the carbonyl group (at the C3 position) of progesterone and the
2/3-OH of the glucose unit of SBE-β-CD in complexes with Isomers 1, 3 and 4 (Fig. 10 and Fig.
11). In contrast, in the complex with Isomer 2, only a few instances of hydrogen bonding occurred
between the carbonyl group of progesterone and the 2/3-OH of the glucose unit of SBE-β-CD.
Interestingly, in Isomer 2, we observed that the carbonyl at the C3 position of Ring A formed
water-mediated hydrogen bonding instead of direct hydrogen bonding with 2-OH or 3-OH of the
glucose unit of SBE-β-CD during the 5 ns simulation (Fig. 10 and 11). During the Pose A
simulations of all four of the isomers, the carbonyl at the C3 position of Ring A was almost always
deeply embedded into SBE-β-CD. In addition, in the Pose B simulations with Isomers 1 and 4 of
SBE-β-CD, there were persistent H-bonds during the simulations (Fig. 10 and 11). The RMSD
analysis revealed that the SBE-β-CD–progesterone complex of all four of the isomers with both
orientations were stable during the entire simulation period. The RMSDs computed with respect
to the initial structure of SBE-β-CD fluctuated between 2.7 and 4.0 Å (Fig. 12 and 13). The RMSD
of progesterone into the four isomeric models of SBE-β-CD fluctuated only between 0.4 to 1.2 Å
(Fig. 12 and 13). The most significant deviations in RMSD were a result of the flexible motion of
the sulfobutyl ether arms.
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Figure 10. An intermolecular hydrogen bond (H-bond) graph for the best complexes between
progesterone and SBE-β-CD (Isomers 1 and 4) observed for 5 ns MD simulation.

33

Intermolecular Hydrogen Bond Counts

2

1

0
0

1000

2000

3000

4000

5000

Time (ps)

Pose A - Isomer-2

Pose A- Isomer-3

Pose B - Isomer-1

Pose B - Isomer-4

Figure 11. An intermolecular hydrogen bond (H-bond) graph between progesterone and SBE-βCD complexes (for each of the four isomers) observed for 5 ns MD simulation.
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Figure 12. RMSD (for all non-hydrogen atoms) plot for the MD simulation (5 ns) of the best
complexes formed between progesterone and SBE-β-CD (Isomers 1 and 4). The brown and purple
lines indicate the RMSD of SBE-β-CD for Isomers 1 (Pose B) and 4 (Pose A), respectively. The
RMSD of progesterone for Isomer 1 (Pose B) and Isomer 4 (Pose A) are represented by red and
orange lines, respectively.
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Figure 13. RMSD (for all non-hydrogen atoms) plot for the MD simulation (5 ns) of the best
complexes formed between progesterone and the four isomeric states of SBE-β-CD (Isomers 1-4).
The red, blue, dark blue and purple lines indicate the RMSD of SBE-β-CD for Isomer 1 (Pose A),
Isomer 2 (Pose A), Isomer 3 (Pose A) and 4 (Pose A), respectively. The RMSD of progesterone
for Isomer 1 (Pose A), Isomer 2 (Pose A), Isomer 3 (Pose A) and Isomer 4 (Pose A) are represented
by yellow, black, green and orange lines, respectively.
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3.3 Solubility of progesterone and SBE--CD–progesterone complex
The results in Table 5 demonstrate that the solubility of progesterone was decreased
compared to its intrinsic solubility in FASSGF, similar to its intrinsic solubility in FESSGF, but
increased 2-fold and 4-fold compared to its intrinsic solubility in FASSIF and FESSIF,
respectively. The main factors influencing oral bioavailability of a drug are solubility of the drug
in gastrointestinal fluid and permeation across the GI barrier. The prerequisite for a drug to
permeate the GI membrane is drug dissolution in GI fluid (3). The drug solubility in GI fluid
depends on the pH and content of the media, but drug pKa and particle size also influence aqueous
solubility. Solubility of weakly basic drugs (e.g., carvedilol) (38) increases in FASSGF, whereas
the solubility of weakly acidic drugs increases in higher pH solvents (FESSGF, FASSIF and
FESSIF) (3). Also, increasing the ionic strength of the buffer increases the solubility of drugs in
GI fluids (38). Progesterone is a neutral compound, so the pH of the GI fluid will only marginally
influence solubility. By comparison, sodium taurocholate and lecithin in FASSIF and FESSIF
form self-aggregates to assist in solubilizing progesterone (39).
Lowering the pH and ionic strength of FASSGF and FESSGF had no effect on the solubility of
the SBE-β-CD–progesterone complex, whereas only 75% and 25% of the SBE-β-CD–
progesterone complex dissolved in FASSIF and FESSIF, respectively. Various studies have
reported that bile salts present in intestinal fluid displace drug molecules from cyclodextrin cavities
leading to precipitation of the drug in the intestinal lumen (9,40,41).
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Table 5. Solubility of progesterone and of the SBE-β-CD–progesterone complex in water and in
simulated gastrointestinal fluid. Each point represents the mean ± SD of triplicate values.
Medium

Progesterone (mM)
Progesterone API

SBE-β-CD–Progesterone

(mM ± S.D.)

Complex (mM ± S.D.)

Water

0.03 ± 0.001

4.998 ± 0.021

FASSGF (pH 1.2)

0.020 ± 0.002

4.869 ± 0.015

FESSGF (pH 5.0)

0.039 ± 0.018

4.299 ± 0.097

FASSIF (pH 6.8)

0.075 ± 0.036

3.311 ± 0.078

FESSIF (pH 6.5)

0.205 ± 0.003

1.020 ± 0.053

3.4 Effect of sodium taurocholate on the isolated SBE-β-CD–progesterone complex mixture
The isolated SBE-β-CD–progesterone complex mixture solubility decreased linearly from
4.94 ± 0.30 mM to 1.64 ± 0.04 mM with linear increase of sodium taurocholate concentration up
to 18 mM, which indicates displacement of progesterone from the cavity of SBE-β-CD (Fig. 14
and Table 6). The progesterone displacement was found to saturate beyond a concentration of 18
mM, which could be the result of formation of sodium taurocholate aggregates (micelles). The size
of sodium taurocholate micelles must be very large to form a complex with SBE-β-CD (42). A
few studies have reported the critical micellar concentration (CMC) of sodium taurocholate to be
8-12 mM or 3-5 mM (43). The CMC of surfactants depends on factors like pH, temperature and
ionic strength of the solvent used (44).
A drug can form a complex with cyclodextrin through non-covalent interactions to form
an inclusion complex. Association and dissociation of drug and cyclodextrin in solvent is rapid.
Upon oral administration of the cyclodextrin–drug complex, the primary mechanism of drug
release from the cyclodextrin cavity is dilution (41). Another mechanism involved in drug release
is the displacement of the drug by certain contents of the GI tract that have a relatively higher
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affinity than the drug to cyclodextrin (41). In the small intestine, displacement of the drug from
the cyclodextrin cavity is reported to be largely by bile salts (40) and to a negligible amount by

Concentration (mM) of Progesterone

lecithin (45).
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Figure 14. Progesterone displacement from the inclusion complex by sodium taurocholate.
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Table 6. Percentage progesterone displacement from the SBE-β-CD–progesterone complex by
sodium taurocholate. Each point represents mean ± SD of triplicate values.

Sodium

Progesterone (%)

Taurocholate (mM)

Mean ± S.D.

0

1.27 ± 0.48

2

1.60 ± 0.49

4

12.0 ± 4.48

6

22.2 ± 4.02

8

19.3 ± 5.24

10

22.2 ± 4.02

12

30.8 ± 4.08

14

44.9 ± 2.99

16

55.2 ± 4.65

18

60.8 ± 1.89

20

67.1 ± 0.81

30

67.9 ± 0.45

40

70.9 ± 0.71

50

69.7 ± 0.59

3.5 Effect of excess SBE-β-CD on sodium taurocholate displacement of progesterone from
SBE-β-CD cavity
The results in Fig. 15 and Table 7 demonstrate that addition of excess SBE-β-CD prevents
the precipitation of progesterone and approximately 40 mM of excess SBE-β-CD is required to
completely counteract displacement of progesterone from cyclodextrin cavities in water. This
indicates that an amount of free SBE-β-CD adequate to form inclusion complexes with bile salts
would prevent precipitation or displacement of progesterone from cyclodextrin.
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The absorption

of a drug is increased if the drug is available in solubilized form at the site of absorption (46). The
cyclodextrin utility number (UCD) equation was derived by Rao and Stella, to calculate the
concentration of cyclodextrin required for complete solubilization of a drug (47). UCD only holds
good for calculating the amount of cyclodextrin required to keep the drug in fully solubilized form
in the absence of bile salts. Olessen et al. (2016), developed a model to calculate the optimum
amount of cyclodextrin to be incorporated in a formulation to prevent the precipitation of the drug
from the cyclodextrin complex in the presence of bile salts (45). This equation does not work well
for the SBE-β-CD–progesterone complex, as there was a ~54-fold difference in stability constant
calculated using the intercept or intrinsic solubility. Employing one definition or the other might
lead to overdosing or underdosing of cyclodextrin. Hence, there is a need to evaluate
experimentally the optimum concentration of cyclodextrin required to fully solubilize the drug in
the presence of bile salts.
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Figure 15. Effect of excess SBE-β-CD (CaptisolTM) on progesterone displacement from the SBEβ-CD–progesterone complex by sodium taurocholate. Each point represents mean ± SD of
triplicate values.
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Table 7. Effect of excess SBE-β-CD on percentage progesterone displacement from the SBE-βCD–progesterone complex by 20 mM of sodium taurocholate. Each point represents mean ± SD
of triplicate values.

SBE-β-CD

Progesterone (%)

(mM)

Mean ± S.D.

0

73.2 ± 0.38

5

55.5 ± 1.92

10

37.0 ± 5.39

20

33.0 ± 1.04

30

23.9 ± 5.00

40

2.87 ± 0.96

50

1.34 ± 1.29

3.6 In vitro simulation to evaluate effect of excess SBE-β-CD on displacement of progesterone
from the SBE-β-CD–progesterone complex in FASSIF and FESSIF
The results in Figs. 16 and 17 and Tables 8 and 9 indicate that an increase in free SBE-βCD in FASSIF and FESSIF prevents displacement of progesterone from the cyclodextrin cavity.
This study demonstrates that the formulation of the SBE-β-CD–progesterone complex
administered in the fasted state or fed state should contain 5 mM and 15 mM free SBE-β-CD,
respectively, to prevent precipitation of progesterone in GI fluids.
The results of section 3.3 indicate that the solubility of the SBE-β-CD–progesterone
complex is different in FESSIF and FASSIF. This might be due to differences in the composition
of the bile salt, lecithin, salt composition or changes in pH of biorelevant media. The CMC of bile
salts depends on the ionic strength and pH of the media (44), hence the CMC of sodium
taurocholate in FASSIF and FESSIF would be completely different from its CMC in water. Also,
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the bile salts might have a different displacement effect on progesterone from the SBE-β-CD

Progesterone Concentration (mM)

complex depending on if it were in water, FASSIF or FESSIF.

FASSIF

5.0
4.0
3.0
2.0
1.0
0.0
0

2

4

6
8
SBE-β-CD (mM)

10

12

Figure 16. Excess SBE-β-CD effect in FASSIF on the solubility of the SBE-β-CD–progesterone
complex. Each point represents mean ± SD of triplicate values.

Table 8. Effect of excess SBE-β-CD on percentage progesterone displacement from SBE-β-CD–
progesterone complex in FASSIF. Each point represents mean ± SD of triplicate values.
SBE-β-CD

Progesterone (%)

(mM)

Mean ± S.D.

0

33.4 ± 1.55

1

31.4 ± 1.61

2

29.4 ± 1.66

3

27.2 ± 1.71

4

25.1 ± 1.76

5

21.2 ± 1.62

7.5

18.8 ± 2.37

10

21.2 ± 2.03
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Figure 17. Excess SBE-β-CD effect in FESSIF on the solubility of the SBE-β-CD–progesterone
complex. Each point represents mean ± SD of triplicate values.

Table 9. Effect of excess SBE-β-CD on percentage progesterone displacement from SBE-β-CD–
progesterone complex in FESSIF. Each point represents mean ± SD of triplicate values.

SBE-β-CD (mM)

Progesterone (%)
Mean ± S.D.

0

79.6 ± 1.05

2.5

64.5 ± 1.32

5

63.6 ± 2.68

7.5

44.8 ± 6.15

10

32.7 ± 2.81

15

19.6 ± 5.83

20

22.4 ± 5.72
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3.7 Stability study
The stability of the SBE-β-CD–progesterone complex in water under two sets of
conditions, 25 °C (60% RH) and 40 °C (75% RH), was ≥ 98.0 and ≥ 97.2% for periods of 3 and 6
months, respectively. The stability of the lyophilized SBE-β-CD–progesterone complex under the
same conditions was ≥ 99.0 and ≥ 97.7% for periods of 3 and 6 months, respectively. Fig. 18
suggests that the SBE-β-CD–progesterone complex in water or in lyophilized form is stable at 25
°C (60% RH) and 40 °C (75% RH) for periods up to 6 months.

SBE-β-CD–Progesterone Complex Stability
% Drug Content

100

99
98
97
96
95
94
25

40

25

3 Month

40
6 Month

Lyophilized

Liquid

Figure 18. Stability of the SBE-β-CD–progesterone complex (lyophilized and liquid) at 25 °C
(60% RH) and 40 °C (75% RH) for periods of 3 and 6 months (n=3) (mean ± S.D.).

3.8 Ex vivo intestinal permeability study
The bioavailability of cyclodextrin upon oral administration is poor, and highly hydrophilic
cyclodextrins have a negligible permeation across the intestinal barrier (48). Upon oral
administration < 3% of SBE-β-CD is absorbed and subsequently it is cleared quickly through renal
excretion, and hence it is non-toxic and has a high safety margin (12,14). Various in vivo (17) and
in vitro (5,40,49) studies suggest the optimum concentration of cyclodextrin required to enhance
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permeability across the intestine or any biological barriers (40,49). Evaluation of a few in vitro
data imply that too little or too much cyclodextrin can decrease the permeability and bioavailability
of a drug (49).
Niels Erik Olesen et al., derived a biopharmaceutical model to assess the effect of
cyclodextrin on intestinal absorption and avoid overdosing of cyclodextrin which could decrease
drug absorption across the intestinal barrier (50). This model employs the K1:1 constant in its
derivation. For poorly soluble drugs the K1:1 value determined from a phase solubility curve is not
a true value; (35) hence this model was not employed for determination of the optimum
concentration of cyclodextrin. Also, simple experimental evaluation of the effect of SBE-β-CD on
drug permeation is more reliable compared to the biopharmaceutical model, since the model
contains exceptions for certain drugs which cannot be employed for all drugs and therefore there
is a risk of an erroneous result.
The ex vivo rat intestinal permeation study results shown in Fig. 19 demonstrate that the
excess SBE-β-CD used in FASSIF and FESSIF had negligible effects on permeation of
progesterone. The intestinal apparent permeability coefficient Papp (Fig. 20) of progesterone in
different groups appeared in the following order: Complex in water > Complex in FASSIF >
Complex in FESSIF with excess SBE-β-CD > Complex in FASSIF with excess SBE-β-CD >
Complex in FESSIF and > Progesterone in 0.5% Brij S20. The ex vivo intestinal permeability study
results depict that if SBE-β-CD is used in the formulation, there is increased permeation of
progesterone across the intestinal barrier.
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Figure 19. Permeation of progesterone across rat intestine: (A) Progesterone in 0.5% of Brij S20;
(B) Complex in water; (C) Complex in FASSIF; (D) Complex in FASSIF with excess SBE-β-CD;
(E) Complex in FESSIF; and (F) Complex in FESSIF with excess SBE-β-CD.
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Figure 20. Apparent intestinal permeability of progesterone: (A) Progesterone in 0.5% Brij S20;
(B) Complex in water; (C) Complex in FASSIF; (D) Complex in FASSIF with excess SBE-β-CD;
(E) Complex in FESSIF; and (F) Complex in FESSIF with excess SBE-β-CD.
48

3.9 Rat pharmacokinetic study
The mean plasma concentration versus time profiles of oral progesterone API, oral SBEβ-CD–progesterone complex and IV progesterone are shown in Fig. 21. It was evident from the
plots that the plasma levels of progesterone were higher when it is administered in the form of the
SBE-β-CD–progesterone complex as compared with progesterone API. Table 6 shows AUC0–1h,
Cmax, Tmax and %Fabs values obtained with oral progesterone API, the oral SBE-β-CD–progesterone
complex and IV progesterone dose. The calculated value for AUC0–1h given in Table. 10 showed
that the overall oral bioavailability of progesterone was increased 5-fold when administered via
the SBE-β-CD–progesterone complex.

Progesterone Plasma Profile
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IV (2 mg/kg)

Progesterone concentration (ng/mL)

PO Progesterone capsule (20 mg/kg)
PO Complex capsule (20 mg/kg)
PO Complex capsule with excess SBE-ß-CD (20 mg/kg)
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Figure 21. Plasma profile of progesterone upon oral administration of SBE-β-CD–progesterone
complex capsule (20 mg/kg), SBE-β-CD–progesterone complex capsule with excess SBE-β-CD
(20 mg/kg), progesterone capsule (20 mg/kg), and IV administered progesterone (2 mg/kg).
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Table 10. Pharmacokinetic parameters of progesterone upon oral administration of a SBE-β-CD–
progesterone complex capsule (20 mg/kg), a SBE-β-CD–progesterone complex capsule with
excess SBE-β-CD (20 mg/kg), a progesterone capsule (20 mg/kg), and IV administered
progesterone (2 mg/kg) in rats.

Pharmacokinetic
Parameters

Formulation
Progesterone
SBE-β-CD –
capsule
progesterone
complex
capsule

Dose (mg/kg)
AUC 0- 1 h (ng.h/mL)
Tmax (min)
Cmax (ng/mL)
% Fabs

20
34.9 ± 15.3
10
52.6 ± 20.4
2.36

20
93.1 ± 5.88
20
151 ± 17.5
6.31

SBE-β-CD –
progesterone
complex capsule
(Excess SBE-βCD)
20
157 ± 22.8
20
267 ± 30.6
10.7

IV
progesterone

2
147 ± 15.6
5
611 ± 59.7
100

3.10 Dissolution studies
The dissolution profiles for progesterone and SBE-β-CD–progesterone complex capsules
in water, SGF and SIF are shown in Fig. 22. The SBE-β-CD–progesterone complex capsules in all
three media have significant improvement in dissolution characteristics compared to progesterone
API capsules. Greater than 95% of progesterone was dissolved in all three media, when testing
SBE-β-CD–progesterone complex capsules for 45 min. By contrast, at 120 min, 11.5, 8.08 and
16.9% of progesterone was dissolved from progesterone API capsule for the three media. The
dissolution parameters of progesterone are given in Table 11. The SBE-β-CD–progesterone
complex capsules had the lowest mean dissolution time (MDT) and highest initial dissolution rate
(IDR) and mean dissolution rate (MDR) in SIF compared to SGF with water as dissolution media.
The progesterone API capsules had the lowest MDT and highest MDR in SIF compared to other
dissolution media (water and SGF), while IDR in water was highest compared to other media (SGF
and SIF).
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GI dissolution and absorption of solid dosage forms depends on GI transit time along with
permeation rates across the GI barrier. These parameters vary in individuals, under disease
conditions, and between the fasted and fed state (51). The gastric lag phase (time taken to empty
10% of the contents from the stomach), gastric half emptying and small bowel transit in fasted
normal healthy volunteered subjects were approximately 55, 180 and 180 min, respectively (52).
In the fed state, gastric half emptying, gastric emptying, small intestine half emptying and transit
through colon were approximately 2.5 to 3, 4 to 5, 2.5 to 3 and 30 to 40 h, respectively (53).
Progesterone tablets are prescribed to be administered at bed time after meals (13). The dissolution
study results imply that SBE-β-CD–progesterone complex capsules would get dissolved in the
stomach (>95% in SGF at 45 min) before entering the small intestine.
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Figure 22. Dissolution of progesterone and of the SBE-β-CD–progesterone complex in water,
simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8).
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Table 11. Progesterone dissolution parameters in water, simulated gastric fluid (SGF, pH = 1.2),
and simulated intestinal fluid (SIF, pH = 6.8).

Formulation

Progesterone Capsule

SBE-β-CD–progesterone
Complex Capsule

Dissolution
Dissolution Parameters
Media
Mean
Mean
Initial
dissolution rate dissolution time dissolution rate
(min-1)
(min)
(min-1)
Water
0.023
48.9
0.001
SGF
0.017
56.0
0.001
SIF
0.037
57.4
0.002
Water
1.210
31.6
0.780
SGF
0.970
25.3
0.710
SIF
1.570
14.9
1.740
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4. Conclusion
The solubility of progesterone in water was enhanced by SBE-β-CD resulting in an AL type
phase solubility curve. Experimental techniques such as DSC, FTIR, 1H and

13

C NMR, and

molecular modeling studies confirmed the formation of a complex between SBE-β-CD and
progesterone. In vitro experiments were employed to determine the amount of SBE-β-CD required
to prevent progesterone displacement from SBE-β-CD cavities and this concentration of SBE-βCD was used in ex vivo intestinal permeation studies. Increased permeation of progesterone across
the membrane was observed. The SBE-β-CD–progesterone complex with excess SBE-β-CD
increased oral bioavailability 5-fold compared to progesterone API suspension. It is of the utmost
importance to consider drug displacement by bile salts in the intestine to avoid underestimation of
oral bioavailability of NCE’s. Also, it is essential to conduct a simple in vitro experiment in early
drug discovery to determine the role of bile salts in displacement of the drug from the cyclodextrin
cavity. It can be very helpful to administer additional amounts of free cyclodextrin to prevent
precipitation of NCE’s in the intestines during preclinical studies. However, the dissolution study
results indicate that SBE-β-CD–progesterone complex capsules get dissolved in the stomach
before entering the small intestine and the addition of excess SBE-β-CD may not be needed, which
would decrease the bulk of the formulation. However, to arrive at the most robust performing
formulation, it may be necessary evaluating the bioavailability of multiple designs with and
without an excess to determine the most advantageous composition.
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CHAPTER 3
Influence of Sulfobutyl-Ether- β-Cyclodextrins on oral bioavailability and tissue
distribution of silymarin

1. Introduction
Silymarin is an extract of Milk Thistle (Silybum marianum) comprises a mixture of
flavonolignans and flavanols. The major constituents of silymarin extracts are taxifolin (TX),
silychristin (SC), silydianin (SD), silybin A (SA), silybin B (SB), isosilybin A (ISA) and isosilybin
B (ISB) (55). These extracts are used as traditional remedies for centuries to treat hepatitis and
cirrhosis and used to protect liver from toxic substances (56,57). In the present-day silymarin is
most extensively investigated drug for the treatment of liver disease and conditions (57). Silymarin
also exhibits a variety of pharmacological activities like anticancer (against prostate, lung,
intestine, colorectal and liver tumors), hypocholesterolemic and cardioprotective effect both
individually and collectively (58). Silymarin is available as a dietary supplement and most widely
used herbal product in United States (59). Silymarin extracts is considered safe herbal product as
there are no severe adverse events reported (60).
The clinical study of silymarin extracts and marketed oral silymarin formulations has
reported high variability in its pharmacokinetic profile (55,61,62), this could result in erratic
pharmacological effect of silymarin constituents. The variability in silymarin pharmacokinetics is
intended to its low aqueous solubility, poor permeation across intestinal barrier and rapid first pass
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metabolism on oral administration (61). Several researchers have endeavored to increase the oral
bioavailability and subsequent therapeutic effect of silymarin constituents employing different
formulation approaches like liposomes (63), phytosomes (64), self microemulsifying drug delivery
systems (65), floating tablets (66), micronization, nanoemulsions (67) and solid dispersions (68).
Most of these formulation approaches were competent to certain extent in increasing the oral
bioavailability of silymarin constituents. However, the commercial feasibility of these
formulations is limited as they lack scalability, stability, reproducibility of physicochemical
properties and dosage form development. Hence, further investigation of simple appropriate
technique to enhance the bioavailability of entire silymarin constituents is essential to avail their
beneficial effects (61).
Solubility enhancement of silymarin constituent is utmost important to increase
bioavailability and to improve drug developability property (3). Aqueous solubility of drugs can
be increased by various techniques, the simple and most commonly employed technique is by
preparation of inclusion complex using cyclodextrins. The lipophilic drugs form an inclusion
complex with cyclodextrins and increases solubility of lipophilic drugs in water. The native and
modified β-cyclodextrin’s (β-CD) have a large cavity size compared to α and γ-CD, hence have
higher aqueous solubility enhancing potential. The native β-CD’s water solubility is low compared
to their derivatives methyl-β-cyclodextrins (M-β-CD), hydroxy-2-propyl-β-cyclodextrins (HP-βCD) and sulfobutyl-ether-β-cyclodextrins (47). The reported studies have demonstrated the utility
of β-CD and HP-β-CD (69) in increasing aqueous solubility of silymarin constituent
silibinin/silybin. The intravenous safety studies of β-CD and M-β-CD have demonstrated they
produce nephrotoxicity in larger doses (10,70). The no observed adverse effect level (NOAEL) for
SBE-β-CD on oral administration in rats is 3600 mg/kg/day, which is >7 times than NOAEL (500
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mg/kg/day) of HP-β-CD (10). Hence, SBE-β-CD are most appropriate cyclodextrins for evaluating
aqueous solubility enhancing potential of active pharmaceutical ingredients intended for oral
formulations.
The objective of this study was to enhance the oral bioavailability of silymarin by preparing
an inclusion complex of SBE-β-CD–silymarin with a simple, less time consuming and efficient
method of complexation. The stability of inclusion complex was evaluated in different simulated
gastrointestinal fluids. To ensure silymarin remains in solubilized form to facilitate its absorption
across intestinal barrier on oral administration of SBE-β-CD–silymarin complex. Ex vivo
permeation studies were performed to evaluate the influence of SBE-β-CD on permeation of
silymarin across porcine intestine. The oral bioavailability of silymarin and its metabolites on oral
administration of SBE-β-CD–silymarin and silymarin complex were evaluated in Sprague Dawley
(SD) rat. The influence of SBE-β-CD on tissue distribution of silymarin on oral administration
was evaluated in SD rats.
2. Materials and Methods
2.1 Chemicals and reagents
Isosilybin and silychristin was purchased from Tractus Company Limited, England.
Silydianin was purchased from ChromaDex Inc. USA. Taxifolin was purchased from Enzo Life
Sciences Inc. USA. Silymarin extract, pepsin, phosphate buffered saline, β-glucuronidase,
sulfatase and L-α-phosphatidylcholine (lecithin) were purchased from Sigma-Aldrich (St. Louis,
MO), USA. SBE-β-CD was a gift sample obtained from Ligand Pharmaceuticals, Inc., USA.
Sodium taurocholate was purchased from Alfa Aesar, USA. Euthasol® (pentobarbital sodium and
phenytoin sodium) solution was procured from Virbac, USA. Methocel E15 Premium EL
(hydroxypropyl methyl cellulose) was a gift sample from Dow Chemical company, USA. The
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HPLC grade solvents acetonitrile, methanol, dibasic potassium phosphate, dibasic sodium
phosphate, glacial acetic acid, hydrochloric acid, sodium hydroxide, sodium chloride, sodium
acetate, ortho-phosphoric acid and Milli Q water were of research grade used without further
purification.

2.2 Estimation of silymarin constituents in silymarin extract
Silymairn is collective term used for main constituents present in extract, structure of
silymarin constituents are depicted in Figure 1. The silymarin extract was weighed and dissolved
in dimethyl sulfoxide (DMSO). These solutions were diluted appropriately using DMSO and the
amount of individual constituents present in each milligram of silymarin extract was estimated by
HPLC method using calibration curve of individual reference standards.

Figure 1. structure of Silymarin constituents.
57

2.3 Physicochemical properties of Silymarin constituents
2.3.1 Solubility of Silymarin constituents
The solubility of silymarin constituents were estimated by adding excess amounts of
silymarin extract in Milli-Q® water, fasted state simulated gastric fluid (FASSGF) at pH 1.6, fed
state simulated gastric fluid (FESSGF) at pH 5.0, fasted state simulated intestinal fluid (FASSIF)
at pH 6.5 and fed state simulated intestinal fluid (FESSIF) at pH 5.8. These gastrointestinal
simulated fluids were prepared by using reported method (34). Samples were kept shaking at 25
°C for 3 days and at equilibrium samples were filtered using a Millipore (0.45 μm) syringe filter.
The filtrate was analyzed using HPLC to evaluate the saturation solubility of individual
constituents of silymarin in water and simulated gastrointestinal fluids.

2.3.2 Simultaneous determination of Log P, Log D and pKa of Silymarin constituents
The Log P, Log D and pKa of silymarin constituents were determined simultaneously by
employing previously published method (71). The 12 buffers between pH ranges of 1.0 to 12 were
prepared using universal buffer stock containing 25 mM hydrochloric acid, 25 mM citric acid, 25
mM phosphoric acid, 30 mM boric acid and 20 mM sodium chloride. To microcentrifuge tubes
500 µL of pre-saturated buffers (1 to 12 pH) with octanol and 500 µL of pre-saturated octanol with
buffers (1 to 12 pH) were added. To above tubes 10 µL of 10 mM DMSO stock solutions of TX,
SC, SD, silybin and isosilybin were added. These mixtures were vortexed for 5 min and kept
shaking at room temperature for 16 h, after specified time these tubes were centrifuged at 10,000
RPM for 30 minutes. After centrifugation buffer and octanol phases were separated, both the
phases were diluted with acetonitrile (1:1) and subjected to HPLC analysis.
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2.4 Phase solubility studies
2.4.1 Conventional Method
SBE-β-CD–silymarin constituents complex were prepared by adding excess of silymarin
extract to different concentrations of SBE-β-CD (10, 20, 40, 60, 80 and 100 mM) in Milli-Q® water
(Higuchi and Connors method) (20). Samples were kept shaking at 25 °C for 3 days and at
equilibrium samples were filtered using a Millipore (0.45 μm) syringe filter. The filtrate was
analyzed using HPLC to evaluate the saturation solubility of silymarin constituents in SBE-β-CD.
Phase solubility study curves were used to calculate complexation efficiency (CE) and stability
constants (K1:1).

2.4.2 Heating Method
SBE-β-CD–silymarin constituents complex were prepared by adding excess of silymarin
extract to different concentrations of SBE-β-CD (10, 20, 40, 60, 80 and 100 mM) in Milli-Q®
water. Samples were kept shaking at 25 °C for 15 minutes and samples were placed on hot plate
stirrer for 60 min at 75 °C temperature. After specified time the samples were cooled at room
temperature and was filtered using a Millipore (0.45 μm) syringe filter. The filtrate was analyzed
using HPLC to evaluate the saturation solubility of silymarin in SBE-β-CD. Phase solubility study
curves were used to calculate complexation efficiency (CE) and stability constants (K1:1).
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2.5 Stability of SBE-β-CD–silymarin complex in simulated gastric fluids
The lyophilized SBE-β-CD–silymarin complex (25 mg) were dissolved in water, FASSGF,
FESSGF, FASSIF and FESSIF. Samples were kept shaking at 37 °C for 8 h at 100 rpm in a Bioshaker and samples were filtered using a Millipore (0.45 μm) syringe filter. The filtrate was
analyzed using HPLC and concentrations of 0 h samples were compared with 8 h samples.

2.6 Stability studies
The lyophilized SBE-β-CD–silymarin complex prepared by heating and conventional
method were stored in a stability chamber under two different conditions, at 40 °C and 75% RH
and at 25 °C and 60% RH. The stability was assessed by evaluating drug content in samples after
3 and 6, 12 months using HPLC.

2.7 Ex vivo porcine intestinal permeation studies
The freshly harvested porcine intestine was obtained from slaughter house and cut open to
expose the mucosal layer and cleaned with PBS pH 7.4. The intestine was sandwiched between
donor and receiver chambers of a franz diffusion cell with an active diffusion area of 0.64 cm 2.
The resistance across porcine intestine was measured using a wave form generator to ensure the
integrity of the small intestine segment used for permeation study. The intestinal membrane with
resistance of ≥2.5 KΩ.cm2 was used for permeation studies. The donor chamber was filled with
0.5 ml of SBE-β-CD–silymarin complex and silymarin in phosphate buffered saline containing
0.5% of Brij S20 used as a positive control. The receiver chamber was filled with 5 ml of PBS (pH
7.4), which was stirred at 600 rpm with a 3 mm magnetic stir bar and the temperature was
maintained at 37 °C with a circulating water bath. 200 μL samples were withdrawn from the
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receiver compartment at different time intervals (0, 1, 2, 4, 6 and 8 h) and each time an equal
volume of fresh receiver media was used to replace withdrawn media. The above samples were
transferred into vials and subjected to HPLC analysis.

2.8 In vivo studies
The animal studies were conducted at University of Mississippi, School of Pharmacy, as
per the protocol #14-021, approved by the institutional animal ethical committee and animal
welfare assurance # A3356-01. On arrival, rats were housed in cages at the animal care facility in
a temperature and humidity controlled room with a 12:12 h light:dark cycle, and they had a free
access to food and water for one week to acclimatize animals before use in the experiments.

2.8.1 Silymarin pharmacokinetic studies in SD rats
Twelve jugular vein cannulated male rats were used for pharmacokinetic studies. These
animals fasted overnight and had free access to water on the day before the experiment. On the
day of the experiment, the rats were removed from the animal care facility and brought to the
procedure lab. Animals were randomly divided into three different groups of 4 animals each
(Group I: PO SBE-β-CD–Silymarin complex; Group II: PO Silymarin API suspension and Group
III: Silymarin intravenous). Dose to animals of group-I and II were administered using rat oral
gavage (fixed to dosing syringe), placed in the mouth and advanced along the lower palate as far
as the esophagus (dosing volume: 10 mL/kg body weight). The dose to group III was administered
by slow bolus intravenous injection into the tail vein (dosing volume: 2 mL/kg body weight). The
dose of individual silymarin constituents administered to animals of different groups are presented
in Table 1. Approximately 200 µL of blood was drawn into heparin-coated tubes at pre-dose, 0.08,
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0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 4 and 8 h through jugular vein catheter. Plasma was harvested by
centrifuging the blood at 4000 rpm for 5 min and stored frozen at 80 ± 10 °C until analysis.
Silymarin constituents in plasma samples were estimated using HPLC.

Table 1. The dose of individual silymarin constituents administered to animals of different groups.

Silymarin

Oral SBE-β-CD–

Oral silymarin

Intravenous SBE-β-

Constituents

silymarin complex

suspension 1000

CD–silymarin complex

mg/kg
Taxifolin

26.2

11.1

5.24

Silychristin

52.5

57.1

10.5

Silydianin

77.1

19.0

15.4

Silybin A

22.4

21.4

4.48

Silybin B

44.0

35.8

8.8

Isosilybin A

27.5

28.2

5.5

Isosilybin B

7.9

7.81

1.58

2.8.2 Estimation of silymarin metabolites in oral pharmacokinetic plasma samples
The silymarin metabolites in plasma were estimated by incubating the plasma samples with
enzymes β-glucuronidase and sulfatase. The β-glucuronidase enzyme was dissolved in 0.1 M
sodium phosphate buffer pH 6.8 to prepare a stock solution containing 2000 units/mL of
glucuronidase. The sulfatase enzyme was dissolved in 0.1 M sodium acetate buffer pH 5.0 to
prepare a stock solution containing 200 units/mL of sulfatase. 25 µL of stock solution of βglucuronidase and sulfatase were added to 2 different 25 µL aliquots of plasma and vortex mixed
for 2 min. These mixtures were incubated at 37 °C for 4 h and after incubation period the enzyme
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activity was terminated by addition of acetonitrile and silymarin constituents were determined
using HPLC.

2.8.3 Silymarin Tissue distribution studies
Male SD rats were used for tissue distribution studies. The animals were fasted overnight
and had free access to water on the day before the experiment. On the day of the experiment, the
rats were removed from the animal care facility and brought to the procedure lab. Animals were
randomly divided into two different groups of 4 animals each (Group I: PO SBE-β-CD–Silymarin
complex and Group II: PO Silymarin API suspension). Dose to animals were administered using
rat oral gavage (fixed to dosing syringe), placed in the mouth and advanced along the lower palate
as far as the esophagus (dosing volume: 10 mL/kg body weight). After 30 min of administration
of oral dose, rats were euthanized using an intraperitoneal (i.p.) dose of Euthasol® (150 mg/kg
body weight). Approximately 200 µL of blood was drawn into heparin-coated tubes and, liver,
lungs, kidney, spleen, heart, ocular and brain tissue were isolated. Plasma was harvested by
centrifuging the blood at 4000 rpm for 5 min. Plasma and tissue samples were stored at 70 ± 10
°C until analysis along. Silymarin constituents in plasma and tissue samples were determined uisng
HPLC.

2.9 HPLC analysis
The HPLC method was developed using a Shimadzu UFLC system, equipped with
prominence SPD-M20A (Diode array detector). The chromatographic separation of silymarin
constituents and the internal standard (IS) dapsone was achieved on a Symmetry Shield RP18
column (150 x 4.6 mm, 5 µm); which was maintained at ambient room temperature. The binary
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mobile phase system reservoir A (Methanol : 10mM Ammonium acetate pH 5 [65:35 v/v]) and
reservoir B (10 mM ammonium acetate pH 5) were run as per gradient program (0-1.9 min: 25%
A and 75% B; 2.0-14.9 min: 80 % A and 20 % B and 15-37.9 min: 80 % A and 20% B and 38-40
min: 25 % A and 75 % B) at a flow rate of 1 mL/min was used throughout the analytical run of 40
min. Samples of solubility, in vitro and ex vivo samples were subjected to HPLC analysis without
any further extraction procedure.
Silybin purchased from Sigma-Aldrich is mixture of SA and SB. The percentage contents
of SA and SB in silybin mixture were analyzed by HPLC and found to be 47.7 and 52.3%,
respectively. Isosilybin purchased from Tractus Company Limited, England is mixture of ISA and
ISB. The percentage contents of ISA and ISB in isosilybin mixture were analyzed by HPLC and
found to be 68.4 and 31.6%, respectively. The measured ratios of SA and SB in silybin and ISA
and ISB in isosilybin were used for the quantitative analysis.

2.10 Recovery
A simple protein precipitation method was employed for extraction of silymarin
constituents from in vivo study samples. The extraction recovery of TX, SC, SD, SA, SB, ISA and
ISB was determined by comparing the peak-area ratios of the analytes from LQC, MQC and HQC
levels spiked in rat plasma, liver, brain, spleen, lungs, kidney, heart and ocular tissue homogenate
(n=3) with the responses of analytes of LQC, MQC and HQC concentrations in acetonitrile.
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2.11 In vivo sample preparation
To an aliquot of 50 µL of rat plasma/enzyme treated samples/tissue homogenate, 5 µL of
dapsone (5 µg/mL) and 200 µL of acetonitrile was added and mixture was vortexed. These samples
were centrifuged at 4 °C for 10 min at 14,000 rpm on a centrifuge 5430R (Eppendorf, Germany)
and the supernatant was transferred to a vial for HPLC analysis. The eluate was monitored by
setting UV detection wavelength at 288 nm. The silymarin constituents and IS was eluted at 7.90,
16.1, 19.1, 20.1, 25.3, 27.0, 32.2 and 34.1 min for IS, TX, SC, SD, SA, SB, ISA and ISB,
respectively.

3. Results and Discussion
Silymarin constituents are low aqueous soluble drugs, and hence its low oral bioavailability
is attributed to low absorption of silymarin across the intestinal barrier. It is important to enhance
the solubility/dissolution of the drug to overcome its poor bioavailability issues and avail beneficial
effects of silymarin constituents.

3.1 Estimation of silymarin constituents in silymarin extract
The silymarin extract is obtained from plant source and different methods are employed to
extract the silymarin. The constituents from the different source consists different proportion of
silymarin constituents. Hence, it is essential to estimate the exact amount of silymarin constituents
present in extract, prior to using the extract for any in vitro or in vivo studies. The amount of
silymarin constituents present in extract is presented in Table 2, SC is the major constituent present
in the silymarin extract. The order of concentrations of silymarin constituents present in silymarin
extract are SC > SA > SB > ISA > SD > TX > ISB.
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Table 2. The amount of silymarin constituents present in each milligram of silymarin extract. Each
point represents mean ± SD of triplicate values.

(µg/mg)

Silymarin Constituents

Mean ± S.D (n=3)

Taxifolin

11.1 ± 0.36

Silychristin

57.1 ± 1.18

Silydianin

19.0 ± 0.57

Silybin A

21.4 ± 0.74

Silybin B

35.8 ± 1.08

Isosilybin A

28.2 ± 0.86

Isosilybin B

7.81 ± 0.26

3.2 Physicochemical properties of Silymarin constituents
3.2.1 Solubility of silymarin constituents in water and simulated gastrointestinal fluids
The solubility of silymarin in water is presented in Table 3, SC have higher and ISB lowest
solubility in water compared to other silymarin constituents. The intrinsic solubility of silymarin
in water was in following order of SC > TX > SD > SB > ISA > SA > ISB. Although silymarin
constituents are derivatives of quercetin (Fig. 1), the solubility of silymarin constituents in water
differs from 1.52 to 145 µg/mL. This indicates the ring other than A, B and C and spatial
arrangements of functional groups attached to E ring of silybin and isosilybin influence the
solubility of silymarin constituents in water (Fig. 1).
The drug solubility in GI fluid depends on physical and chemical properties of drug and
GI fluid. GI fluid’s ionic strength and content of the media influence solubility of drug (39). Drug
solubility in GI fluid and permeation across GI barrier are two crucial factors governing the oral
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bioavailability of a drug, drugs as to be dissolved in GI fluid to permeate across the GI membrane
(3). The solubility of drug in water might not be an indicative of their solubility in GI fluids. Hence,
it’s essential to determine the solubility of drug molecule in GI simulated fluids intended for oral
administration. The ionized form of drug has higher solubility in water compared to their unionized
counterparts. The weakly basic drugs are predominantly ionized and solubilized in FASSGF,
whereas weakly acidic salts are predominantly ionized and solubilized in FESSGF, FASSIF and
FESSIF (3).
The solubility of TX in FASSIF was decreased by ~20%, whereas solubility of TX in other
simulated gastrointestinal fluids (SGIF) was unchanged (Table 3). The percentage solubility of
SC, SD, SA, SB, ISA and ISB in FASSGF decreased to 65.2, 66.9, 9.86, 10.6, 14.3 and 10.5% of
water solubility, respectively (Table 3). The percentage solubility of SC, SD, SA, SB, ISA and
ISB in FASSIF decreased to 69.6, 72.4, 62.6, 30.7, 41.5 and 57.2% of water solubility, respectively
(Table 3). The decrease in the solubility of SC, SD, SA, SB, ISA and ISB in FASSGF, FESSGF
and FASSIF could be due to pH of the media (39). The solubility of SC, SD, SA, SB, ISA and ISB
were increased in FESSGF by 1.24, 1.65, 9.04, 6.31, 10.6, 13.9 fold compared to water solubility,
respectively (Table 3). Increase in FESSGF solubility might be due to presence of bile salt and
lecithin in FESSGF media (39).
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Table 3. The solubility of silymarin constituents (µg/mL) in Milli-Q® water and simulated
gastrointestinal fluids. Each point represents mean ± SD of triplicate values.

Silymarin

FASSGF

FESSGF

FASSIF

FESSIF

Constituents

Milli-Q® water

(pH 1.6)

(pH 5.0)

(pH 6.5)

(pH 5.8)

Taxifolin

135 ± 3.31

123 ± 8.30

129 ± 7.35

97.7 ± 2.63

125 ± 4.23

Silychristin

145 ± 9.87

94.6 ± 5.31

101 ± 4.65

71.3 ± 6.18

181 ± 13.4

Silydianin

55.9 ± 1.56

37.4 ± 0.29

40.5 ± 2.39

27.3 ± 1.13

92.2 ± 2.55

Silybin A

3.45 ± 0.45

0.34 ± 0.04

2.16 ± 0.17

1.37 ± 0.04

31.2 ± 0.69

Silybin B

11.0 ± 0.24

1.17 ± 0.06

3.38 ± 0.02

4.78 ± 0.20

69.4 ± 1.68

Isosilybin A

7.29 ± 0.20

1.04 ± 0.05

3.03 ± 0.22

2.79 ± 0.15

77.0 ± 2.84

Isosilybin B

1.52 ± 0.03

0.16 ± 0.00

0.87 ± 0.05

0.67 ± 0.03

21.2 ± 0.39

3.2.2 Simultaneous determination of Log P, Log D and pKa of Silymarin constituents
Despite silymarin is most extensively studied for various in vitro and in vivo
pharmacological activities, the physicochemical properties of individual constituents are yet to be
determined experimentally. Lipophilicity (Log P and Log D) and dissociation constant (pKa) is an
intrinsic property of a molecule, which are most important factors influencing absorption,
distribution, metabolism and excretion of a drug. These factors are used in early discovery to
predict the in vivo pharmacokinetics and to facilitate formulation development (71). The Log D is
logarithmic ratio of drug concentration in octanol to drug concentration in buffer of particular pH.
The Log P is the logarithmic ratio of drug concentration in octanol to drug concentration in aqueous
phase, as the unionized form. The pKa of silymarin constituents were calculated by plotting the
measured Log D (pH) as a function of apparent pH described by Po-Chang Chiang et al (71).
The results in Table 4 demonstrates Log P and Log D (pH 7.4) of silymarin constituents
are in following order ISB > ISB > SB = SA > SD > SC > TX and ISA ≥ ISB ≥ SA ≥ SB > SC >
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TX ≥ SD, respectively. The pKa of all silymarin constituents were in range of 5.57 to 6.10 (Table
4). The plot of Log D (pH) vs pH in Figure 2 depicts all silymarin constituents are weakly acidic
drugs and they remain unionized in entire pH range of GI tract and consequently, decrease in the
solubility of SC, SD, SA, SB, ISA and ISB in FASSGF, FESSGF and FESSIF (Table 3). This plot
indicates, if silymarin constituents are administered in solubilized form their absorption would be
rapid in entire GI tract.

Table 4. The Log P, Log D and pKa of silymarin constituents. Each point represents mean ± SD
of triplicate values.

Silymarin Constituents

Log P

Log D (pH 7.4)

pKa

Taxifolin

1.06 ± 0.06

0.19 ± 0.01

5.79 ± 0.02

Silychristin

1.51 ± 0.01

1.06 ± 0.01

5.82 ± 0.11

Silydianin

1.16 ± 0.05

0.14 ± 0.08

5.57 ± 0.13

Silybin A

2.29 ± 0.03

1.77 ± 0.01

6.03 ± 0.03

Silybin B

2.26 ± 0.07

1.80 ± 0.01

6.10 ± 0.10

Isosilybin A

2.55 ± 0.40

1.89 ± 0.03

5.85 ± 0.52

Isosilybin B

2.69 ± 0.27

1.94 ± 0.07

5.70 ± 0.35
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Figure 2. The Log D vs pH of silymarin constituents. Each point represents mean ± SD of triplicate
values.

3.3 Phase Solubility
The phase solubility curve (Figure 3) of silymarin prepared by both methods (conventional
and heating) depicts a linear increase in solubility of silymarin constituents as a function of
increase in concentration of SBE-β-CD, indicating an AN type curve (47). The affinity (stability)
constants (K1:1) and complexation efficiencies (CE) of SBE-β-CD–silymarin constituents were
calculated from slope and intercept of phase solubility curve.
Equation 1. Stability constant
𝑲𝟏:𝟏 = 𝑺

𝒎

𝟎 (𝟏−𝒎)

Equation 2. Complexation efficiency
𝒎

𝑪𝑬 = (𝟏−𝒎)
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where m is the slope of the curve obtained by plotting the drug solubility versus
cyclodextrin concentration, determined by linear regression. The CE and K1:1 of the SBE--CD–
silymarin complex are presented in Table 5. The CE and K1:1 of silymarin constituents were
calculated considering the intrinsic solubility of silymarin constituents in water. The increase in
the solubility of silymarin constituents was higher, when heating method was used compared to
conventional method. The formation of cyclodextrin–drug inclusion complex depends on their
steric arrangement and thermodynamic factors. The complexation process involves dislodging of
water molecule from the hydrophobic cavity and formation of hydrogen bond interactions between
cyclodextrin and drug molecule (72). In heat method, on increasing the temperature to 75 °C of
the cyclodextrin–silymarin mixture, the process of water molecule removal from hydrophilic
cavity of cyclodextrin is accelerated and favors the accommodation of drug moiety into the cavity.
The conventional method requires longer duration for cyclodextrin to attain equilibrium with drug
molecule, this could be 3 to 7 days differ from molecule to molecule. In case of heating method,
the time taken is only 60 minutes and can be used for molecules which are stable at 75 °C, this
method can be easily adopted for scaleup process in industries.
The solubility of TX, SC, SD, SA, SB, ISA and ISB in 100 mM of SBE--CD prepared
using heating method was found to be increased by 12.2, 36.2, 138, 650, 400, 377 and 522 folds
compared to their intrinsic solubility, respectively (Figure 4). The solubility of TX, SC, SD, SA,
SB, ISA and ISB in 100 mM of SBE--CD prepared using conventional method was found to be
increased by 9.57, 33.3, 124, 262, 231, 316 and 442 folds compared to their intrinsic solubility,
respectively (Figure 5). The K1:1 of SBE--CD–silymarin constituents complex were in the order
of ISB > ISA > SA > SB > SD > SC > TX and ISB > SA > SB > ISA > SD > SC > TX for
complexes prepared by conventional and heating method, respectively (Table 5). The stability
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constant of silymarin constituent complexes prepared by both methods are directly proportional to
Log P of silymarin, this indicates increase in lipophilicity of molecule have higher affinity to
cyclodextrin cavity (Table 4 and 5).

Silymarin Concentration (mM)

60
50
40
30
20
10
0
0

20

40
60
Captisol Concentration (mM)
Heating Method

80

100

Conventional Method

Figure 3. Phase solubility profile of Silymarin in SBE-β-CD by heating and conventional method.
Each point represents mean ± SD of triplicate values.
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Number Fold increase in solubility

800
700
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400
300
200
100
0
Taxifolin

Silychristin

Silydianin

Silybin A

Conventional

Silybin B

Isosilybin A Isosilybin B

Heating

Figure 4. Number fold increase in solubility of silymarin constituents by SBE-β-CD prepared
using heating and conventional method. Each point represents mean ± SD of triplicate values.
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Table 5. Solubility of silymarin constituents in 100 mM SBE-β-CD, complexation efficiency (CE) and stability constant (K1:1) of
silymarin constituents in SBE-β-CD prepared using heating and conventional method. Each point represents mean ± SD of triplicate
values.

Heating

Conventional

Constituents

(mM ± S.D.)

CE

K1:1

(mM ± S.D.)

CE

K1:1

Taxifolin

5.43 ± 0.52

0.038 ± 0.006

85.4 ± 13.6

4.24 ± 0.33

0.025 ± 0.001

58.4 ± 4.16

Silychristin

10.9 ± 0.48

0.123 ± 0.009

409 ± 29.9

10.0 ± 0.65

0.106 ± 0.004

355 ± 13.4

Silydianin

16.0 ± 0.35

0.207 ± 0.011

1784 ± 93.2

14.4 ± 0.98

0.170 ± 0.007

1471 ± 63.6

Silybin A

4.65 ± 0.20

0.049 ± 0.002

6889 ± 306

1.88 ± 0.16

0.018 ± 0.001

2578 ± 130

Silybin B

9.13 ± 0.31

0.106 ± 0.006

4665 ± 247

5.28 ± 0.37

0.054 ± 0.002

2368 ± 89.0

Isosilybin A

5.70 ± 0.14

0.068 ± 0.005

4474 ± 308

4.77 ± 0.41

0.051 ± 0.003

3405 ± 167

Isosilybin B

1.64 ± 0.05

0.019 ± 0.001

6056 ± 256

1.39 ± 0.13

0.014 ± 0.001

4560 ± 308
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Silymarin

3.4 Solubility of SBE--CD-silymarin complex in simulated GI fluids
The drug to get absorbed across the membrane barriers, drug has to be in their solubilized
form at the site of absorption (47). To ensure the silymarin remains in their solubilized form in GI
fluids on oral administration, its essential to evaluate the stability and solubility of SBE--CDsilymarin complex in simulated GI fluids.
There was no change in solubility of silymarin, except for SBE--CD-SD the solubility
was decreased in FASSIF and FESSIF by 33.4 and 14.7 %, respectively. The decrease in solubility
of SD could be due to contents of FESSIF and FASSIF displacing the SD from the cavity of SBE-CD. Previous reported studies have demonstrated sodium taurocholate and lecithin present in
intestinal fluid displaces progesterone from HP-β-CD-progesterone complex (19).

Table 6. Solubility of SBE-β-CD–Silymarin complex in water and in simulated gastrointestinal
fluid. Each point represents the mean ± SD of triplicate values.

Silymarin

Water

FASSGF

FESSGF

FASSIF

FESSIF

constituents

(µg/mL)

(%)

(%)

(%)

(%)

Taxifolin

292 ± 1.27

100 ± 0.73

101 ± 1.03

97.0 ± 2.06

98.1 ± 1.36

Silychristin

868 ± 2.71

100 ± 1.15

100 ± 1.58

97.1 ± 1.32

93.7 ± 1.09

Silydianin

234 ± 3.23

100 ± 1.47

101 ± 2.05

66.6 ± 3.45

85.3 ± 1.73

Silybin A

159 ± 0.52

102 ± 1.26

101 ± 0.88

100 ± 1.89

97.7 ± 0.74

Silybin B

369 ± 1.68

101 ± 0.84

101 ± 0.90

99.2 ± 1.75

98.1 ± 1.12

Isosilybin A

443 ± 2.51

101 ± 0.72

101 ± 1.22

98.2 ± 1.40

96.0 ± 1.62

Isosilybin B

124 ± 0.97

100 ± 1.30

101 ± 2.08

100 ± 1.76

95.3 ± 2.75
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3.5 Stability studies
The stability of the lyophilized silymarin complex prepared by conventional method under
two sets of conditions, 25 °C (60% RH) and 40 °C (75% RH), was ≥ 94.4 and ≥ 90.1% for periods
12 months, respectively (Figure 5). The stability of the lyophilized silymarin complex prepared by
heating method under two sets of conditions, 25 °C (60% RH) and 40 °C (75% RH), was ≥ 92.2
and ≥ 94.2% for periods 12 months, respectively (Figure 5).
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Conventional Method
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Silybin A

40 °C

Silybin B

Isosilybin A Isosilybin B
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Heating Method

% Stability
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Silybin A
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Silybin B
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Figure 5. Stability of the lyophilized SBE-β-CD–silymarin complex prepared by heating and
conventional methods at 25 °C (60% RH) and 40 °C (75% RH) for periods of 12 months. Each
point represents the mean ± SD of triplicate values.
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3.6 Ex vivo porcine intestinal permeation studies
The ex vivo porcine intestinal permeation study results shown in Figure 6 demonstrates that
the SBE-β-CD–silymarin constituents complex have higher permeability compared to silymarin
constituents dissolved in PBS containing 0.5% of Brij S20. The silymarin was dissolved in PBS
containing 0.5% of Brij S20, as they are not soluble in aqueous media Brij S20 was used to
facilitate the solubilization. The intestinal apparent permeability coefficient Papp of silymarin was
in following order for TX > SD > SC > SA ≥ SB ≥ ISA ≥ ISB and ISB > SA > SB > ISA > SC >
TX ≥ SD, respectively. The lag phase for silymarin constituents dissolved in Brij S20 for TX, SC
were 2 h and for SD, SA, SB, ISA and ISB were 4 h, In case of SBE-β-CD–silymarin complex
there was no lag phase observed.
The intestinal apparent permeability coefficient Papp of TX, SC, SD, SA, SB, ISA and ISB
from SBE-β-CD–silymarin constituents complex was 4.80, 20.5, 10.2, 67.1, 77.7, 40.9 and 117
fold higher compared to silymarin constituents dissolved in PBS containing 0.5% of Brij S20,
respectively. The permeation across barrier was directly proportional to partition coefficient and
concentration gradient of a compound across the barrier (Table 4, 5 and 7, Figure 6). The ex vivo
intestinal permeability study results indicate SBE-β-CD used in the formulation increased
permeation of silymarin across the intestinal barrier. The enhancement of permeation was due to
increasing in concentration gradient across the barrier and SBE-β-CD’s permeation enhancing
effect on barrier.
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Figure 6. Permeation of silymarin across rat intestine: Silymarin in 0.5% of Brij S20 and SBE-βCD–silymarin complex in water. Each point represents the mean ± SD of sextuplicate values.
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Table 7. Apparent intestinal permeability (Papp) of silymarin: SBE-β-CD–silymarin complex in
water and silymarin in 0.5% of Brij S20. Each point represents the mean ± SD of sextuplicate
values.

Silymarin Constituents

SBE--CD–silymarin

Silymarin in 0.5% of Brij S20

complex
Taxifolin

4.51 ± 0.72

0.94 ± 0.22

Silychristin

5.94 ± 0.87

0.29 ± 0.18

Silydianin

4.47 ± 0.71

0.44 ± 0.08

Silybin A

18.8 ± 2.47

0.28 ± 0.07

Silybin B

17.1 ± 2.27

0.22 ± 0.10

Isosilybin A

8.59 ± 1.27

0.21 ± 0.06

Isosilybin B

26.8 ± 3.39

0.23 ± 0.07

3.7 Recovery
The simple protein precipitation method was employed for extraction of Silymarin
constituents from plasma and tissue homogenate. As silymarin constituents have good solubility
in acetonitrile and methanol. The extraction trials were performed with acidified and alkalinized
acetonitrile and methanol for enhancing the recovery of analytes from biological samples and to
precipitate proteins. At different concentration level (LQC and HQC) of each analyte the recovery
was evaluated, and peak area ratio was considered for the calculations. The results (Table 8)
demonstrated the recovery of TX, SD, SC, SA, SB, ISA and ISB from different matrices were
concentration independent and reproducible with the use of acetonitrile (without acidification nor
alkalinization).
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Table 8. The percentage recovery of Silymarin constituents in rat plasma and tissue homogenate.

Taxifolin

Silychrsitin

Silydianin

Silybin A

Silybin B

Isosilybin A

Isosilybin B

Plasma

Liver

Spleen

Brain

Lungs

Heart

Kidney

Ocular

LQC

Conc.
(ng/mL)
91.2

84.1 ± 7.59

89.5 ± 1.90

95.7 ± 3.03

93.8 ± 10.3

103 ± 3.22

96.5 ± 4.59

99.3 ± 7.22

95.5 ± 6.02

HQC

3162

79.9 ± 1.39

97.9 ± 8.14

93.0 ± 2.95

101 ± 3.86

103 ± 3.49

91.9 ± 1.89

100 ± 3.61

89.5 ± 7.65

MQC

4864

77.9 ± 5.57

93.5 ± 6.55

109 ± 3.49

106 ± 2.51

101 ± 6.98

99.5 ± 1.94

106 ± 4.15

88.5 ± 4.96

LQC

145

95.3 ± 3.90

90.1 ± 7.21

92.9 ± 7.17

104 ± 2.00

85.8 ± 2.57

101 ± 5.82

99.1 ± 9.26

87.0 ± 3.48

HQC

5017

103 ± 2.40

90.9 ± 4.08

93.9 ± 1.46

91.9 ± 4.57

97.3 ± 2.65

90.0 ± 0.86

87.9 ± 2.14

85.3 ± 6.62

MQC

7719

100 ± 8.01

94.7 ± 5.05

94.3 ± 2.48

92.6 ± 5.02

96.3 ± 4.11

92.8 ± 0.21

90.3 ± 3.71

85.5 ± 4.05

LQC

145

96.2 ± 7.37

96.8 ± 9.05

91.1 ± 4.63

99.2 ± 12.3

97.9 ± 9.27

93.0 ± 4.66

101 ± 6.47

86.5 ± 6.69

HQC

5017

101 ± 5.75

94.9 ± 6.03

108 ± 1.92

94.5 ± 2.09

105 ± 15.00

104 ± 0.09

98.8 ± 1.35

93.9 ± 9.03

MQC

7719

92.0 ± 2.72

96.2 ± 2.55

96.6 ± 3.15

87.1 ± 2.04

102 ± 5.65

97.1 ± 0.23

96.5 ± 3.90

85.4 ± 4.61

LQC

72.4

94.3 ± 6.76

86.7 ± 1.76

102 ± 7.31

103 ± 3.98

99.5 ± 4.57

97.5 ± 5.09

86.7 ± 1.37

74.0 ± 4.09

QC levels

HQC

2509

105 ± 2.01

91.1 ± 3.83

94.6 ± 2.10

91.3 ± 4.99

96.8 ± 1.65

89.2 ± 1.72

87.9 ± 1.34

83.1 ± 6.54

MQC

3860

102 ± 8.27

99.9 ± 5.32

94.3 ± 2.16

97.3 ± 1.66

94.1 ± 5.52

91.6 ± 0.39

89.3 ± 3.73

81.5 ± 4.84

LQC

72.4

90.1 ± 5.36

96.6 ± 9.54

96.5 ± 7.66

103 ±12.3

96.7 ± 7.75

93.4 ± 4.21

102 ± 10.7

86.7 ± 5.64

HQC

2509

103 ± 3.56

92.0 ± 3.71

93.5 ± 1.79

91.9 ± 5.09

97.5 ± 3.21

89.7 ± 0.34

88.4 ± 1.73

85.3 ± 7.03

MQC

3860

99.9 ± 8.86

99.1 ± 5.44

94.4 ± 1.85

96.4 ± 1.91

95.3 ± 4.53

92.5 ± 0.16

87.5 ± 0.60

82.8 ± 2.57

LQC

109

104 ± 3.36

97.4 ± 1.91

98.2 ± 4.46

99.1 ± 2.85

99.0 ± 2.68

82.4 ± 4.36

95.3 ± 7.73

71.7 ± 1.73

HQC

3763

103 ± 4.07

92.0 ± 2.55

94.0 ± 1.62

90.2 ± 5.89

96.5 ± 2.60

88.4 ± 1.94

88.1 ± 1.49

84.0 ± 6.56

MQC

5789

98.7 ± 9.74

99.6 ± 5.17

94.3 ± 1.96

96.3 ± 2.07

95.4 ± 4.57

92.1 ± 0.60

89.9 ± 3.66

84.7 ± 2.76

LQC

36.2

100 ± 5.17

97.0 ± 15.2

86.4 ± 8.49

98.6 ± 4.32

102 ± 4.97

104 ± 7.76

94.1 ± 4.12

76.0 ± 2.28

HQC

1254

103 ± 3.62

93.0 ± 3.79

95.3 ± 1.98

91.3 ± 4.57

96.4 ± 3.14

88.7 ± 0.05

86.9 ± 1.40

83.4 ± 6.20

MQC

1930

99.1 ± 9.27

99.3 ± 5.53

95.6 ± 1.83

95.9 ± 1.76

95.0 ± 5.03

93.0 ± 0.73

89.2 ± 3.73

86.8 ± 4.65
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Matrix (n=3) mean ± SD
Silymarin

3.8 In vivo pharmacokinetic studies
As the silymarin is most extensively used herbal supplement and clinically studied for
various pharmacological activities, it is essential to the study pharmacokinetics of all seven
constituents of silymarin in preclinical models prior to testing on human subjects. The plasma
profile of silymarin oral bioavailability depicts AUC of silymarin are higher in group of animals
administered with SBE-β-CD–silymarin complex compared to group administered with silymarin
suspension. The Figure 7 demonstrates, absorption of silymarin was faster and higher in SBE-βCD–silymarin complex group compared to silymarin suspension group. The AUC considered for
determining the relative oral bioavailability of TX, SC, SD, SA, SB, ISA and ISB was 0 to 60, 0
to 60, 0 to 30, 0 to 120 min, 0 to 120 min, 0 to 120 min and 0 to 90 min, respectively (Figure 7 and
Table 9). The relative oral bioavailability of TX, SC, SA, SB, ISA and ISB in SBE-β-CD–
silymarin complex group was found to be increased by 1.31, 2.37, 3.51, 2.82, 6.64 and 5.71
compared to silymarin suspension group, respectively (Table 9). This study demonstrates SBE-βCD–silymarin complex would be better formulation for enhancing the oral bioavailability of TX,
SC, SA, SB, ISA and ISB.
The relative bioavailability of SD was same in both groups SBE-β-CD–silymarin complex
and silymarin suspension group, there was no influence of SBE-β-CD. Previous reported studies
have demonstrated, bile salt in intestinal fluid replaces drug from cyclodextrin cavity leading to
precipitating the drug in intestinal lumen and thus decreasing the drug absorption (19,41,42). The
above studies demonstrate, the decrease in bioavailability of SD could be due to their lower log P
and displacement of SD from SBE-β-CD–SD complex by GI contents of FASSIF and FESSIF by
33.3 and 14.7%, respectively.
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Figure 7. Plasma profile of taxifolin(A), silychrsitin(B), silydianin(C), silybin A(D), silybin B(E),
isosilybin A(F) and isosilybin B(G) upon oral administration of SBE-β-CD–silymarin complex,
silymarin suspension, and IV administered SBE-β-CD–silymarin complex. Each point represents
the mean ± SD of quadruplicate values.
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Parameters
Dose (mg/kg/BW)
AUC 0- 2 h (ng.h/mL)
Tmax (min)
Cmax (ng/mL)
T1/2
% Fabs
Dose (mg/kg/BW)
AUC 0- 2 h (ng.h/mL)
Tmax (min)
Cmax (ng/mL)
T1/2 (min)
% Fabs
Dose (mg/kg/BW)
AUC 0- 2 h (ng.h/mL)
C0 (ng/mL)
Cmax (ng/mL)
T1/2
Cl (ml)
Vd (L/kg)

Oral silymarin suspension
Taxifolin
Silychristin Silydianin Silybin A
Silybin B
11.1
57.1
19.0
21.4
35.8
107 ± 14.2
116 ± 30.7
50.0 ± 8.90 248 ± 11.0
283 ± 35.5
30
20
20
30
30
191 ± 34.6
256 ± 65
202 ± 54.4 223 ± 19.1
276 ± 50.4
NA
NA
NA
204 ± 23.1
70.1 ± 9.31
0.71 ± 0.22 2.55 ± 0.52 1.98 ± 0.10
1.52 ± 0.22
1.93 ± 0.29
Oral SBE--CD–Silymarin complex
26.2
52.5
77.1
22.4
44.0
241 ± 30.2
982 ± 146
391 ± 44.3
204 ± 15.9 907 ± 89.4
20
20
20
20
20
538 ± 102
673 ± 101
752 ± 91.6 1438 ± 153
1260 ± 173
58.3 ± 4.05
NA
57.6 ± 18.6
66.3 ± 2.39
NA
1.68 ± 0.24 2.56 ± 0.23 6.94 ± 0.79
4.28 ± 0.73
2.52 ± 0.34
Intravenous SBE-β-CD–silymarin complex
5.24
10.5
15.4
5.24
8.80
2625 ± 158
2862 ± 420 1601 ± 45.8 3061 ± 210
4584 ± 404
11147 ± 1878 19962 ± 5483 9241 ± 588 11316 ± 759 16418 ± 3393
7907 ± 816
10839 ± 1321 6183 ± 797 7950 ± 318
12737 ± 2356
54.7 ± 6.43
43.0 ± 13.4 44.7 ± 5.57 27.3 ± 1.21
42.5 ± 0.83
28.5 ± 1.30
58.2 ± 7.39 135 ± 3.79 27.6 ± 1.62
28.8 ± 2.30
2.26 ± 0.35
3.25 ± 0.66 8.67 ± 0.96 1.09 ± 0.10
1.76 ± 0.11

Isosilybin A
28.2
136 ± 9.25
20
167 ± 30.3
79.7 ± 21.0
1.01 ± 0.08

Isosilybin B
7.81
300 ± 24.5
20
458 ± 65.3
88.2 ± 14.8
2.66 ± 0.25

27.5
878 ± 22.4
30
876 ± 102
48.5 ± 4.38
6.64 ± 0.20

7.9
1729 ± 141
30
1911 ± 180
40.7 ± 2.58
15.2 ± 1.42

5.50
2886 ± 111
6700 ± 1330
4973 ± 564
60.7 ± 13.5
18.3 ± 2.06
1.57 ± 0.16

1.58
2279 ± 117
4765 ± 456
4213 ± 349
60.8 ± 5.70
9.17 ± 0.91
0.80 ± 0.07

Note: NA: Due levels were below limit of quantitation in plasma samples elimination phase was not able to capture to calculate T1/2

84

Table 9. The silymarin dose administered to animals and pharmacokinetic parameters of silymarin in rats on oral administration of
silymarin suspension and SBE--CD–silymarin complex, and intravenous administration of SBE-β-CD–silymarin complex. Each point
represents the mean ± SD of quadruplicate values.

3.9 Estimation of silymarin metabolites in oral pharmacokinetic plasma samples
Although aqueous solubility and ex vivo intestinal permeation of silymarin was increased
by several folds by SBE-β-CD and no displacement of TX, SD, SA, SB, ISA and ISB from SBEβ-CD cavity in GI fluids, the oral bioavailability increase of SBE-β-CD–silymarin was
approximately 1.31- 6.64 folds. The decrease in oral bioavailability could be due to extensive first
pass metabolism and elimination of silymarin (62,73). In present study, the oral plasma samples
were treated with glucuronidase and sulfatase enzyme to estimate the unconjugated, glucuronide
conjugate, sulfate conjugate and total (free and conjugated) silymarin. The concentration of total
silymarin in oral plasma samples would suggest the extent of silymarin absorption on oral
administration. The AUC of unconjugated, conjugated and total silymarin on oral administration
of silymarin suspension and SBE-β-CD–silymarin are depicted in Figure 8A and B, respectively.
The Tmax of glucuronide and sulfate conjugate TX, SC, SD, SA, SB, ISA and ISB was
same as Tmax of unconjugated/free silymarin on oral administration. The AUC of total TX, SC,
SD, SA, SB, ISA and ISB was increased by 10.5, 28.0, 16.8, 22.9, 15.0, 14.0 and 10.5 fold
compared to unconjugated/free silymarin on oral administration of silymarin suspension,
respectively. The AUC of total TX, SC, SD, SA, SB, ISA and ISB was increased by 12.6, 35.4,
22.1, 39.2, 22.7, 21.3 and 17.7 fold compared to unconjugated/free silymarin on oral
administration of SBE-β-CD–silymarin, respectively. The results demonstrate 64.4 and 27.8% of
silymarin are present as glucuronide and sulfate conjugate on oral administration of silymarin
suspension, respectively and 68.7 and 27.2% of silymarin are present as glucuronide and sulfate
conjugate on oral administration of silymarin suspension. This study indicates the extent of
absorption was increased on oral administration of SBE-β-CD–silymarin complex compared to
silymarin suspension and the percentage of metabolite formed was same in both groups.
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Figure 8. The AUC0-t of free silymarin, glucouronide silymarin conjugate, sulphate silymarin
conjugate and total silymarin in rat plasma on oral administration of silymarin suspension(A) and
SBE--CD–silymarin complex(B) in rat plasma. Each point represents the mean ± SD of
quadruplicate values.
86

3.10 Silymarin tissue distribution
Over 30 clinical studies have carried out to evaluate the potential therapeutic effects of
silymarin extract or silibinin or used as an adjunct drug along with other therapeutic agents in
management and treatment of various disorders like diabetic nephropathy, hepatitis, tuberculosis,
leukemia, nonalcoholic fatty liver disease, prostate cancer, upper gastrointestinal adenocarcinoma,
liver toxicants, metastatic colorectal cancer, galactagogues effect, Beta-Thalassemia major and
steatosis. These clinical studies have been carried out by administering Legalon®, Silymarin
phytosome and silymarin extract, most of the studies have shown inconsistent study results
attributed to its low and variable oral bioavailability (<10% in humans) (74). Hence, it is important
to evaluate the amount of silymarin distributed to its target organ in preclinical species prior to
evaluating the therapeutic effect of silymarin in humans.
The concentration of silymarin in different tissue are presented in Figure 9. On oral
administration of silymarin formulations, silymarin constituents TX, SC, SD, SA, SB, ISA and
ISB levels were found in lungs, kidney and liver. All constituents were found in spleen except SD
and ISB, whereas only SB and SC levels were found in brain and, SC, ISA, SA and SB were found
in heart. The total amount of silymarin present in liver, brain, spleen, lungs, kidney and heart was
found to be 1172, 326, 334, 988, 535 and 260 ng/gm of tissues on oral administration of SBE-βCD–silymarin complex. The total amount of silymarin present in liver, brain, spleen, lungs, kidney,
heart and ocular was found to be 2377, 310, 739, 6804, 1141, 350 and 125 ng/gm of tissues on oral
administration of SBE-β-CD–silymarin complex.
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Figure 9. The concentrations of silymarin constituents TX, SC, SD, SA, SB, ISA and ISB in (A) spleen, (B) liver, (C) kidney, (D) lungs,
(E) heart, (F) brain and (G) ocular on oral administration of silymarin suspension and SBE-β-CD–silymarin complex

4. Conclusion
The solubility of silymarin in water was enhanced by SBE-β-CD with an AN type phase
solubility curve and heating method was found to be more efficient with less time consuming. The
solubility of SBE-β-CD–TX, SC, SA, SB, ISA and ISB complex solubility in GIF was not
changed, SBE-β-CD–SD solubility was decreased in FASSIF and FESSIF. The ex vivo intestinal
permeation of silymarin was increased on SBE-β-CD complexation. There was no effect of SBEβ-CD on oral pharmacokinetics of SD, whereas oral bioavailability of TX, SC, SA, SB, ISA and
ISB were increased by 1.31 to 6.64 folds on oral administration of SBE-β-CD–silymarin complex
compared to silymarin suspension. The studies indicate 92.2 and 95.9% of absorbed drug are
rapidly metabolized on oral administration of silymarin suspension and SBE-β-CD–silymarin,
respectively. This study demonstrates heating method can be employed to scale-up the preparation
of stable SBE-β-CD–silymarin complex. The tissue distribution studies showed increased levels
of silymarin constituents in plasma and tissue samples on oral dosage of SBE-β-CD–silymarin
complex and compared to the group dosed with silymarin suspension. This study demonstrates the
SBE--CD-silymarin complex would be a better alternative to enhance the tissue exposure and
oral bioavailability of silymarin constituents.
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CHAPTER 4
Development of SBE--CD-silymarin Topical Formulation
1. Introduction
Silybum marianum fruits and seeds are used for over 2000 yrs (74) for mitigation of
cirrhosis, hepatitis and to protect liver from amanita toxins (56,57). The major constituents of
silymarin extract comprises of taxifolin (TX), silychristin (SC), silydianin (SD), silybin A (SA),
silybin B (SB), isosilybin A (ISA) and isosilybin B (ISB) (55). In recent times, the extract of
Silybum marianum seeds (silymarin) is most extensively studied for variety of pharmacological
activities (75). The in vitro, preclinical and clinical studies have demonstrated silymarin possesses
a dermatological beneficial effect in treatment of UV induced erythema, melanoma, nonmelanoma skin cancer, rosacea, melasma, vitiligo, psoriasis and wound healing (76).
The rate limiting step for absorption of silymarin is solubility and the systemic
bioavailability of silymarin may be enhanced by increasing solubility (61). The solubility
enhancement of BCS class II drug and thus its dermal bioavailability is the most challenging
aspects of drug development process of topical drug delivery system. Cyclodextrin inclusion
complex preparation technique is most commonly employed to improve the aqueous solubility (7).
Our initial studies have demonstrated solubility of silymarin in water was enhanced by SBE-β-CD
with an AN type phase solubility curve and the increase in aqueous solubility of TX, SC, SD, SA,
SB, ISA and ISB was 12.3, 36.2, 138, 650, 400, 377 and 522-fold compared to intrinsic aqueous
solubility, respectively.
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The objective of present study is to determine in-vitro dermal kinetics of silymarin
constituent in human skin models and develop SBE-β-CD–silymarin topical formulation and their
evaluation. The non-specific binding of silymarin to human skin and intrinsic skin clearance of
silymarin in human skin model was determined. The porcine skin penetration of SBE-β-CD–
silymarin was evaluated and permeation enhancers were screened to potentiate the silymarin
penetration. The SBE-β-CD–silymarin topical formulation was developed by incorporation of
permeation enhancers and optimized the formulation to stabilize the cream and to increase the
permeation of silymarin across skin and penetration of silymarin into skin (human cadaver).

2. Materials and Methods
2.1 Chemicals and reagents
Isosilybin and silychristin was purchased from Tractus Company Limited, England. Silydianin
was purchased from ChromaDex Inc. USA. Taxifolin was purchased from Enzo Life Sciences Inc.
USA. Silymarin extract, silibinin (silybin), D-ɑ-tocopheryl polyethylene glycol succinate, taurine,
Tween 80, phenyl piperazine, Dimethicone and phosphate buffered saline were purchased from
Sigma-Aldrich (St. Louis, MO), USA. SBE-β-CD was a gift sample obtained from Ligand
Pharmaceuticals, Inc., USA. Sodium taurocholate was purchased from Alfa Aesar, USA.
Euthasol® (pentobarbital sodium and phenytoin sodium) solution was procured from Virbac,
USA. Methocel E15 Premium EL (hydroxypropyl methyl cellulose) was a gift sample from Dow
Chemical company, USA. Polyethylene glycol 400, propylene glycol, octyldodecanol, light
mineral oil, macrogol cetostearyl ether 20, cetostearyl alcohol, cremophor A 25 macrogolglycerol
ricinoleate, cremophor A6, glycerol monostearate, cetostearyl alcohol 50, cetostearyl alcohol 70
and stearic acid were gift samples obtained from BASF chemicals company, USA. Transcutol was
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a gift sample obtained from Gattefosse SAS, France. The HPLC grade solvents acetonitrile,
methanol, dibasic potassium phosphate, dibasic sodium phosphate, glacial acetic acid,
hydrochloric acid, sodium hydroxide, sodium chloride, sodium acetate, ortho-phosphoric acid and
Milli Q water were of research grade used without further purification.

2.2 HPLC analysis
The HPLC system consisted of Waters system equipped with performance PLUS inline
degasser along dual λ absorbance detector set at 288 nm. The chromatographic separation of
silymarin constituent was achieved on a Symmetry Shield RP18 column (150 x 4.6 mm, 5 µm);
which was maintained at ambient room. The binary mobile phase system consisted of reservoir A
(Methanol : 10mM Ammonium acetate pH 5 [65:35 v/v]) and reservoir B (10 mM ammonium
acetate pH 5) were run as per gradient program (0-1.9 min: 25% A and 75% B; 2.0-14.9 min: 80
% A and 20 % B and 15-37.9 min: 80 % A and 20% B and 38-40 min: 25 % A and 75 % B). A
flow rate of 1 mL/min was used throughout the analytical run.

2.3 In vitro Human skin Binding
The Human skin drug protein binding of silymarin was evaluated by modified charcoal
adsorption method (77). In this method, charcoal was coated with dextran by addition of 0.6 gm
of charcoal to 100 mL of DPBS containing 0.06% dextran and stirred with a magnetic stirrer at
room temperature. The volume of charcoal suspension required for the experiment was
determined. To 15 mL centrifuge tubes 2 (A), 4 (B) and 6 (C) mL of charcoal suspensions were
added and centrifuged at 4000 rpm for 30 min. After centrifugation supernatant was carefully
decanted and spiked with 1 mL of 10 µM TX, SC, SD, silibinin and isosilybin to charcoal pellets
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of 2, 4 and 6 mL in triplicates. These tubes were stirred and immediately centrifuged at 4000 RPM
for 30 min, the supernatant was analyzed for silymarin constituents using HPLC. The tubes at
which no silymarin constituents were detected was selected for human skin binding assay, as the
pellets can completely adsorb unbound silymarin constituents.
Human cadaver skin was minced into smaller pieces and weighed. To 1 gm of skin 4 mL
of Dulbecco's Phosphate-Buffered Saline pH 7.4 was added and homogenate using tissue
homogenizer. The skin homogenate was equilibrated for 30 min with 10 μM of silymarin
constituents (n=3) in triplicates and transferred to centrifuge tube containing pellet of dextran
coated charcoal by continuous stirring at 37 °C. The serial samples were withdrawn from the above
mixture at 0, 2, 5, 10 and 15 min and centrifuged at 4000 rpm for 10 min. The supernatant was
separated and silymarin constituents from supernatant were extracted and subjected to HPLC
analysis.

2.4 In vitro human skin clearance
2.4.1 In vitro human skin S9 fraction clearance

The S9 fractions is tissue homogenate containing cytochrome P450 isoforms (phase I
enzymes) and phase II enzymes. The pooled mixed gender human skin S9 fraction was procured
from BioIVT company, USA was used for skin clearance studies. TX, SC, SD, silibinin, isosilybin
and testosterone at 10 μM was preincubated at 37 °C with human skin S9 fraction (1 mg/mL) in
66.7 mM phosphate buffer pH 7.4 for 5 min. After preincubation nicotinamide adenine
dinucleotide phosphate (NADPH) and uridine diphosphate glucuronic acid (UDPGA) was added
to above mixture and incubated for 0, 15, 30, 60, 90 and, 120 min. One aliquot was incubated for
120 min (without NADPH and UDPGA), to study any chemical instability or non-NADPH and
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UDPGA dependent enzymatic degradation. The reaction was terminated by adding ice-cold
quenching solution, and centrifuged for 15 min at 13,000rpm. The supernatant was transferred to
a vial and subjected to HPLC analysis to evaluate the amount of silymarin constituents present in
the incubation mixture at different time intervals.

Data analysis
Elimination rate constant (ke) is slope obtained by plotting % disappearance vs time
➢

T½= -0.693/ke

➢

S9 fraction intrinsic clearance (µL/min/mg) = (Elimination rate constant * Volume of
incubation µL) / protein in incubation (mg)

➢

Intrinsic clearance (µL/min/kg) = S9 fraction intrinsic clearance * protein yield from the
human skin S9 fraction

2.4.2 In vitro Human epidermal keratinocyte and dermal fibroblast clearance
2.4.2.1 Human epidermal keratinocyte Cell culture
The human epidermal keratinocyte cells were maintained at 37 °C in a humidiﬁed
atmosphere of 5% CO2 and 90% relative humidity. The Keratinocytes-serum free growth medium
with 50 ng/mL human recombinant endothelial growth factor and 2 mM L-glutamine
supplemented with 10% fetal bovine serum, penicillin (100 mg/mL) and streptomycin (100
mg/mL) was used for cell growth. The medium was replaced every other day in flask and when
the cells reached 80-90% confluence, cells were detached using Trypsin-ethylene diamine tetra
acetic acid (EDTA). The detached cells were plated at a density of 0.5 million cells/well in 96well culture plates.
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2.4.2.2 Human dermal fibroblast Cell culture
The human dermal fibroblast cells were maintained at 37 °C in a humidiﬁed atmosphere
of 5% CO2 and 90% relative humidity. The fibroblast basal medium supplemented with 10% fetal
bovine serum, fibroblast growth kit-low serum, penicillin (100 mg. mL-1) and streptomycin (100
mg. mL-1) was used for cell growth. The medium was replaced every other day in flask and when
the cells reached 80-90% confluence, cells were detached using Trypsin-EDTA. The detached
cells were plated at a density of 0.5 million cells/well in 96-well culture plates.

2.4.2.3 In vitro human epidermal keratinocyte and dermal fibroblast clearance
On attaining cell confluence of 90–95% in 96–well plates, these plates were used for
metabolic stability studies. The medium was aspirated, and human epidermal keratinocytes /
dermal fibroblasts cells were treated with growth medium consisting of 10 µM of TX, SC, SD,
silibinin, isosilybin and testosterone in sextuplets. The drug treated plates were incubated for 0, 6,
12, 18 and 24 h. After incubation period, the reaction was terminated by adding ice-cold
acetonitrile containing 0.1% formic acid and internal standards (dapsone). The 96 well plates were
centrifuged at 4000 rpm for 10 min and supernatant subjected to HPLC analysis to evaluate the
amount of silymarin constituents present in the incubation mixture at different time intervals. The
assay validity was assessed by use of positive control testosterone which is extensively
metabolized by skin metabolic enzymes.
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Data analysis
Elimination rate constant (ke) is slope obtained by plotting % disappearance vs time
➢ t½= -0.693/ke
➢ V (µL/106 Cells) = Incubation volume (µL) / Number of cells in incubation (106)
➢ Intrinsic clearance (µL/min/million cells) = V*0.693 / t½

2.5 In vitro Release, Ex vivo Permeation and Penetration Testing
In vitro release, ex vivo permeation and penetration testing of silymarin formulations were
performed using Franz diffusion cells.

2.5.1 Preparation of Porcine epidermis
The freshly isolated porcine belly skin was obtained from the slaughterhouse. The skin was
cut into smaller pieces and washed with phosphate buffered saline. The subcutaneous layer and
hair were removed from skin. The skin was wrapped in an aluminum foil and placed in water bath
for 2 min at 60 °C. Immediately the epidermis was peeled off from the skin and the epidermis was
stored at 4 °C.

2.5.2 Preparation of Human cadaver skin
The human cadaver skin was obtained from New York Firefighters skin bank, NY, USA.
Cryo-preserved skin was thawed at 32 °C and cut into circular sections. The thawed skin was
washed with PBS pH 7.4 thoroughly and used for ex vivo permeation and penetration studies.
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2.5.3 Methodology
Nylon membrane of pore diameter 0.2 µm was used for the in vitro release studies. Nylon
membrane or porcine skin epidermis or human cadaver skin was sandwiched between two
chambers of a Franz diffusion cell with an active diffusion area of 0.64 cm2, and the stratum
corneum surface was exposed to the donor chambers. The resistance across porcine skin epidermis
and human skin cadaver was measured using a wave form generator to ensure the integrity of skin
segment. Porcine skin epidermis and human cadaver skin with resistance of ≥10 KΩ.cm2 was used
for permeation and penetration studies. The receiver chamber was filled with 5 mL of PBS 7.4 pH
containing 0.5% of Brij, which was constantly stirred with help of magnetic stir bar at 600 rpm.
The whole Franz diffusion cell assembly was maintained at 32 ± 1 °C with the help of thermostatic
water circulator. The formulation was loaded onto donor chamber. At predetermined time intervals
samples were withdrawn through the sampling port of Franz diffusion cells and equal volume of
fresh receptor fluid was replaced. After the study, skin was removed and washed thoroughly to
remove the formulation or drug from the surface of skin. The skin was weighed, minced into
smaller pieces and homogenized using homogenizer. The silymarin content in the receptor fluid
and homogenate was determined using HPLC.

2.6 Extraction method
A simple protein precipitation method was used for extraction of silymarin constituents
from in-vitro and ex-vivo study samples. To an aliquot of 50 µL of skin homogenate / in-vitro
samples, an internal standard solution (5 µL of dapsone 5 µg/mL) was added and the mixture was
vortexed. To above samples 200 µL of acetonitrile was added and the mixture was vortexed. The
sample was centrifuged at 4 °C for 10 min at 14,000 rpm on a Centrifuge 5430R (Eppendorf,
Germany) and the supernatant was transferred to a vial for HPLC analysis. The silymarin
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constituents and IS eluted at 7.90, 16.1, 19.1, 20.1, 25.3, 27.0, 32.2 and 34.1 min for IS, TX, SC,
SD, SA, SB, ISA and ISB, respectively with a total run time of 40 min.

2.7 Screening of permeation enhancers
The permeation enhancers were screened to enhance the penetration of SBE-β-CD enabled
silymarin in to porcine epidermis. Ex vivo penetration studies performed as explained in section
2.5. To the donor compartment 500 µL of 10% D-ɑ-tocopheryl polyethylene glycol succinate
(TPGS), 5% taurine, 10% tween 80, TPGS:Tween 80 (5:5%), 0.15% phenyl piperazine, 20%
polyethylene glycol (PEG) 400, 20% propylene glycol (PG) and 10% transcutol in SBE-β-CD–
silymarin complex and 500 µL of control silymarin dissolved in 0.5% of Brij S20 were loaded for
studies. After 24 h donor chamber was emptied out and porcine epidermis was removed. Silymarin
content in porcine skin homogenate and receptor fluid was determined using HPLC.

2.8 Development of SBE--CD-silymarin Topical Formulation
The SBE--CD-silymarin cream was developed by incorporating penetration enhancers.
The different excipients were evaluated to stabilize the cream formulation. In oil phase emollients
octyldodecanol (OD) (2 to 5%) and light mineral oil (9 to 12%); emulsifiers macrogol cetostearyl
ether 20 (MCSE) (1 to 5%), cetostearyl alcohol (3 to 7.5%), cremophor A 25 macrogolglycerol
ricinoleate (1.5 to 5%), cremophor A6 (1 to 3%), glycerol monostearate (GMS) (1 to 5%); viscosity
enhancing agents cetostearyl alcohol 50 (CSA 50) (2 to7%), cetostearyl alcohol 70 (CSA 70) (2 to
7%) and stearic acid (2 to 5%) were screened and defoaming agent dimethicone (0.5%). In
aqueous phase SBE--CD-silymarin (complex), penetration enhancers and glycerin as humectant
was used.
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2.8.1 Cream preparation
The SBE--CD-silymarin cream was prepared by conventional method using Silverson
Homogenizer L5M-A (Silverson Machines INC, USA). The Oil phase was heated separately at 70
°C. The aqueous phase heated at 70 °C in beaker, where the temperature was controlled with a
circulating water bath and stirred. The oil was added slowly with the constant stirring to the
aqueous phase. Both the phases were homogenized for 120 minutes at 1000 rpm min with
temperature-controlled program as depicted in Figure 1. Transcutol was added at 75th min of
homogenization, when the temperature reaches below 50 °C.

Figure 1. Silverson homogenizer and temperature program used for preparation of SBE--CDsilymarin cream.
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2.8.2 Freeze thaw cycle testing of cream
The creams prepared were subjected to Freeze-thaw cycle testing to determine the stability
of cream at extreme temperature conditions. The Freeze-thaw testing was performed by exposing
cream to freezing conditions (approximately -20 °C) for 24 h and allowed to thaw at room
temperature for 24 h. These creams were then placed at higher temperature (approximately 45 °C)
for 24 h and then placed at room temperature again for 24 h. The sample was visualized for
significant changes in consistency and stable formulations were further subjected to 2 more cycles
of freeze thaw testing (78). After three cycles of freeze thaw, the consistency of creams, pH and
globule size of stable formulation were evaluated and compared with formulations stored at room
temperature (not exposed to freeze thaw).

2.8.3 Measurement of cream pH
The stability and solubility of drug constituents in topical drug formulation is dependent
on pH of creams. The pH of creams significantly influences the ionization of drug, thus
solubilization of drug in formulation and leading to changes in permeability of drug across skin
(79). The pH of stable creams (fresh creams and creams subjected to Freeze thaw test) was
measured using Mettler Toledo pH meter, equipped with In-Lab® Micro pH probe. The probe was
placed in creams and ensured cream is in uniform contact with active surface of pH probe to record
pH. After recording pH, excess cream on the probe was wiped off and washed with de-ionized
water. After washing, two more readings of cream pH were recorded.
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2.8.4 Globule Size
The distribution of globule size in creams influence permeation of the drug across
biological barrier (80). Hence, here in this study distribution of globule size was evaluated to study
the effect of freeze thaw on microstructure of creams. Approximately 10 mg of cream was directly
weighed on a clean microscope glass slide and a film applicator was placed on the slide such that
the clearance between applicator blade (Gardco® Microm II applicator blade, Japan) and the glass
slide was set to 10 µm. The tail of applicator was slightly tilted upwards. By application of slight
pressure on slide, the applicator was pulled slowly to form a uniform film. The film was
immediately focused using 60X magnification under DSC mode, using Olympus microscope and
pictures were captured. The diameter of 100 globules was randomly measured using Cell Sens
software. The d10, d50 and d90 were extrapolated from the cumulative frequency Vs globule size
plot.

2.8.5 In vitro release testing of SBE--CD–silymarin Topical Formulation
The SBE--CD-silymarin creams with minimal changes in pH and globule size post Freeze
thaw cycle were subjected to in vitro release testing. In vitro release testing was performed as
described in section 2.5, donor compartment was loaded with 300 mg of SBE--CD–silymarin
cream covering the entire active diffusion area. The donor compartment was sealed with parafilm
to simulate infinite conditions (81). The receptor fluids were withdrawn at 0, 0.5, 1, 2, 3, 4, 5 and
6 h time intervals. The concentration of drug in aliquots were analyzed using HPLC.
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2.8.6 In vitro permeation testing of SBE--CD–silymarin cream
The SBE--CD–silymarin creams possessing good in vitro release characteristics were
subjected to ex vivo permeation and penetration testing. Ex vivo permeation testing was performed
as described in section 2.5, creams were applied at 15 mg/cm2 on the epidermal surface of skin
using a spatula. Silymarin content in skin homogenate and receptor fluid collected at 24 h was
determined using HPLC.
One SBE--CD–silymarin creams with good ex vivo permeation and penetration were
selected. This formulation was evaluated for ex vivo human cadaver skin penetration at 6, 12, 18
and 24 h time intervals and receptor fluid were collected to determine the amount permeated across
the skin. The concentration of drug in receptor fluid and homogenate were analyzed using HPLC.

2.9 SBE--CD–silymarin topical formulation stability.
The final SBE--CD–silymarin cream was packed in screw capped HDPE bottles and
stored in a stability chamber under two conditions, at 40 °C and 75% RH and at 25 °C and 60%
RH. After period of 3 months, the stability of cream was assessed by evaluating drug content using
HPLC.

3. Results and Discussion
3.1 In vitro Human skin Binding
The human skin drug binding is essential to determine for drugs intended for dermal or
transdermal drug delivery. The non-specific drug binding effects the therapeutic efficacy of drug.
Only unbound drug would permeate across the skin or penetrate skin to produce its therapeutic
activity. Initial silymarin binding to dextran coated charcoal studies demonstrated, the dextran
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coated charcoal pellet present in tube B (4 mL charcoal suspension) completely adsorbed the
spiked silymarin constituents. The tube B was selected to further evaluate the in vitro human skin
binding of silymarin.
The percent drug remaining in the supernatant was plotted versus time, this curve was fitted
to a two-compartment model using Phoenix WinNonlin software (Version 1.5) with intravenous
bolus input using a non-linear regression (77). The Cmax value at time 0 min is extent of human
skin protein bound drug and percentage bound is calculated from Cmax at 0 min. The silymarin
bound to human skin components was in the order of SC > TX > SB > ISA > ISB > SA > ISB and
extend of drug bound is presented in Table 1. The study results demonstrate activity of ̴ 7.63% of
silymarin delivered to skin is uncertain. As, in case of skin the blood flow is low, hence
maintaining equilibrium between bound and unbound drug is difficult compared to plasma protein
drug binding.
Table 1. Percentage of drug bound to human skin components (n=3).

Parameters

% Bound
(mean ± SD)

Taxifolin

10.4 ± 1.88

Silychrsitin

12.3 ± 0.49

Silydianin

7.30 ± 1.43

Silybin A

6.30 ± 1.22

Silybin B

7.77 ± 1.59

Isosilybin A

7.31 ± 1.03

Isosilybin B

2.09 ± 0.49
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3.2 In vitro human skin clearance
Skin contains several enzymes that could potentially lead to biotransformation of drugs
during permeation. The extent of biotransformation of drug in the skin should be considered as a
prerequisite for development of a transdermal drug delivery system. Results from this study can
be used to standardize the dose of silymarin required to be incorporated in the formulation to
produce its beneficial effects on skin. Substrate depletion method was employed for determining
intrinsic clearance and half-life by plotting percentage remaining against time. Testosterone was
used as a control in in-vitro human skin clearance studies. Previously reported studies have
demonstrated testosterone is extensively metabolized in skin (82).

3.2.1 In vitro human skin S9 fraction clearance
The Figure 2 depicts the percentage remaining against time curve of silymarin and
testosterone. The percentage drug metabolized, half-life and intrinsic clearance of silymarin and
testosterone is presented in Table 2. The half-life of silymarin was in order of SB > ISA > ISB >
SC > SA > TX > SD in Human skin S9 fraction. The studies demonstrated SD was most
extensively cleared and SB was least cleared in human skin S9 fraction. The 74.2% of testosterone
was metabolized at 2 h in human skin S9 fraction, demonstrating the validity of assay conditions.
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Figure 2. Testosterone (control) and silymarin percentage metabolized with time in human skin
S9 fraction (n=3).
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Table 2. Percentage metabolized, half-life and intrinsic clearance of testosterone (control) in
presence of human skin S9 fractions (n=3).

Half life
Parameters

S9 Intrinsic clearance

% Metabolized

(t1/2) min

Testosterone

74.2 ± 3.92

64.4 ± 21.3

10.8 ± 1.14

Taxifolin

28.8 ± 4.34

258 ± 42.3

2.73 ± 0.45

Silychrsitin

20.2 ± 2.49

417 ± 34.1

1.67 ± 0.14

Silydianin

72.3 ± 2.47

70.3 ± 2.76

9.87 ± 0.39

Silybin A

23.1 ± 8.54

397 ± 87.0

1.80 ± 0.38

Silybin B

9.17 ± 0.12

953 ± 132

0.74 ± 0.10

Isosilybin A

15.0 ± 2.74

565 ± 117

1.26 ± 0.26

Isosilybin B

17.1 ± 1.48

433 ± 84.1

1.64 ± 0.31

(µL/min/mg)

The human skin S9 fractions procured from BioIVT was mixed gender and pooled fraction.
As per the certificate analysis of BioIVT, these fractions have demonstrated Uridine 5'-diphosphoglucuronosyltransferase (phase I) and CYP3A4 (phase II) enzyme activity.

3.2.2 In vitro Human epidermal keratinocyte and dermal fibroblast clearance
Human epidermal keratinocyte and dermal fibroblast clearance study was developed and
validated to study the metabolism of drugs in human skin model and predict skin clearance. The
Figure 3 depicts the percentage remaining against time curve of silymarin and testosterone. The
percentage drug metabolized, half-life and intrinsic clearance of silymarin and testosterone is
presented in Table 3. The half-life of silymarin was in order of SB > SC > TX > SA > ISB > SD
> ISA in human epidermal keratinocyte. The studies demonstrated ISA was most extensively
cleared and SB was least cleared in human skin S9 fraction. The 75.8 % of testosterone was
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metabolized at 24 h in human epidermal keratinocyte, demonstrating the validity of assay
conditions.
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Figure 3. Testosterone (control) and silymarin percentage metabolized with time in human
epidermal keratinocytes (n=4).
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Table 3. Percentage metabolized, half-life and intrinsic clearance of testosterone (control) in
presence of human epidermal keratinocytes (n=4).

Half life
Parameters

Intrinsic clearance

% Metabolized

(t1/2) h

Testosterone

75.8 ± 3.20

13.0 ± 1.19

267 ± 25.5

Taxifolin

32.0 ± 2.44

43.5 ± 3.00

79.8 ± 5.41

Silychrsitin

25.2 ± 0.60

56.0 ± 3.40

62.0 ± 3.66

Silydianin

62.6 ± 1.77

17.9 ± 0.75

194 ± 8.13

Silybin A

34.2 ± 1.50

41.3 ± 3.02

84.1 ± 6.40

Silybin B

25.3 ± 1.48

60.7 ± 3.21

57.2 ± 3.11

Isosilybin A

70.3 ± 0.63

15.1 ± 0.55

230 ± 8.67

Isosilybin B

66.2 ± 3.36

19.4 ± 1.33

179 ± 12.1

(µL/hr/106 cells)

The Figure 4 depicts the percentage remaining against time curve of silymarin and
testosterone. The percentage drug metabolized, half-life and intrinsic clearance of silymarin and
testosterone is presented in Table 4. The half-life of silymarin was in order of ISA > SC > ISB >
TX > SA > SB > SD in human dermal fibroblasts. The studies demonstrated SB was most
extensively cleared and SC was least cleared in human dermal fibroblasts. The 64.5 % of
testosterone was metabolized at 24 h in human dermal fibroblast, demonstrating the validity of
assay conditions.
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Figure 4. Testosterone (control) and silymarin constituent percentage metabolized with time in
human dermal fibroblasts (n=3).
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Table 4. Percentage metabolized, half-life and intrinsic clearance of testosterone (control) in
presence of human dermal fibroblasts (n=3).

Parameters

Intrinsic clearance

% Metabolized

Half life (t1/2) h

Testosterone

64.5 ± 4.93

15.9 ± 1.94

128 ± 62.3

Taxifolin

43.8 ± 12.7

33.2 ± 12.1

114 ± 42.5

Silychrsitin

43.8 ± 12.7

35.0 ± 15.6

70.7 ± 55.3

Silydianin

48.0 ± 6.38

25.8 ± 1.57

82.7 ± 53.3

Silybin A

40.4 ± 4.16

32.2 ± 6.80

111 ± 21.6

Silybin B

45.7 ± 2.78

29.0 ± 1.84

120 ± 7.84

Isosilybin A

32.3 ± 2.31

45.2 ± 3.35

76.9 ± 5.90

Isosilybin B

38.7 ± 2.08

34.8 ± 3.39

100 ± 10.3

(µL/hr/106 cells)

The extent of silymarin metabolism in human epidermal keratinocytes and dermal
fibroblast were different. This study indicates the enzyme milieu present in both cells are
completely different. Hence, it’s essential to evaluate the clearance of drugs intended for dermal
and transdermal drug delivery in both cell lines to avail the beneficial therapeutic effects of drugs.

3.3 Screening of permeation enhancers
The drugs should permeate across the skin or penetrate skin to produce its intended
therapeutic activity in dermatological disorders. The effect of different permeation enhancers on
the penetration of SBE-β-CD enabled complex is presented in Table 5. The SC, SD, SA, SB and
ISA penetrated from SBE-β-CD–silymarin complex, whereas no silymarin constituents were
penetrated the skin from control (silymarin dissolved in 0.5% of Brij S 20). Demonstrating SBEβ-CD have intrinsic skin penetration enhancing property. Further, series of permeation enhancers
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were screened to potentiate the skin penetration effect of SBE-β-CD. Among, all enhancers
screened polyethylene glycol 400, propylene glycol and transcutol increased the skin penetration
of all constituents TX, SC, SD, SA, SB, ISA and ISB. Propylene glycol was found to be more
efficient in increasing skin penetration compared to other enhancers. In presence of 20% of
propylene glycol, skin penetration of SC, SD, SA, SB and ISA was increased by 12.2, 18.8, 5.55,
9.50 and 6.89-fold compared to SBE-β-CD–silymarin complex without enhancer, respectively.
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Table 5. Effect of permeation enhancer on the penetration of SBE-β-CD enabled silymarin constituents into the porcine epidermis

Silymarin constituents (ng)/ mg of epidermis after 24h (Mean ± SEM) n=6
Enhancers used in
Taxifolin

Silychristin

Silydianin

Silybin A

Silybin B

Isosilybin A

Isosilybin B

(n=6)

(n=6)

(n=6)

(n=6)

(n=6)

(n=6)

(n=6)

Control

BLQ

BLQ

BLQ

BLQ

BLQ

BLQ

BLQ

Blank

BLQ

50 ± 3.89

81.3 ± 7.41

20.4 ± 4.82

32.4 ± 6.21

31.3 ± 5.12

BLQ

TPGS (10%)

BLQ

127 ± 9.54

116 ± 9.32

69.9 ± 10.2

63.9 ± 5.87

54.2 ± 7.41

32.8 ± 4.06

Taurine (5%)

BLQ

110 ± 11.5

327 ± 76.2

48.8 ± 6.23

96.4 ± 14.8

67.6 ± 10.2

24.8 ± 4.17

Tween 80 (10%)

BLQ

56.1 ± 6.32

63.9 ± 7.61

33.0 ± 3.91

49.5 ± 7.84

27.2 ± 2.86

20.9 ± 3.67

TPGS : Tween 80 (5 : 5%)

5.22 ± 1.2

59.9 ± 4.81

78.6 ± 8.93

34.6 ± 3.47

43.2 ± 9.23

27.2 ± 5.23

22.8 ± 3.14

Phenyl piperazine (0.15%)

16.4 ± 6.83

92.6 ± 11.8

68.5 ± 5.87

36.0 ± 5.76

67.1 ± 7.95

56.9 ± 7.48

26.9 ± 1.89

PEG 400 (20%)

7.12 ± 1.75

86.3 ± 6.41

135 ± 8.89

45.6 ± 7.84

55.7 ± 6.32

69.4 ± 10.2

34.2 ± 2.32

Propylene glycol (20%)

44.8 ± 2.62

616 ± 69.1

1525 ± 182

113 ± 16.2

308 ± 45.1

216 ± 26.4

61.9 ± 3.48

Transcutol (20%)

35.8 ± 4.45

348 ± 35.7

468 ± 36.9

57.8 ± 11.9

128 ± 17.4

106 ± 17.1

26.2 ± 1.43

complex

* Control (silymarin in 0.5% of Brij 20), Blank (SBE-β-CD–silymarin complex), BLQ: Below limit of quantitation, NA: Not applicable.
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SBE-β-CD–silymarin

3.4 Development of SBE--CD–silymarin Topical Formulation
Oil in water (O/W) SBE--CD–silymarin cream was prepared by incorporating PG 20%
and transcutol 5% as penetration enhancers. In creams, the composition of aqueous phase was
SBE--CD–silymarin complex (57%), PG (20%), transcutol (5%) and glycerol (1%). The aqueous
composition of creams was kept constant and composition of oil phase was optimized to prepare
a stable cream.
Two sets of creams were prepared, 1st set of creams was prepared with oil composition of
light mineral oil (9 to 12%), cremophor A 25 macrogolglycerol ricinoleate (2 to 4%), cremophor
A6 (1 to 2%) and cetostearyl alcohol (3 to 8%). Decreasing the concentration of emulsifier
cremophor A 25 macrogolglycerol ricinoleate <3% and viscosifying agent concentration <3%
resulted in phase separation of creams. The 2nd set of creams was prepared with oil composition
of OD (3 to 12%), CSA 50 (2 to 7%), CSA 70 (2 to 7%), MCSE 20 (1 to 5%) and GMS (1 to 4%).
As the concentration of viscosifying agents decreased to <2% resulted in phase separation of
creams.

3.4.1 Freeze thaw cycle testing of cream
Creams stable at room temperature for 7 days was exposed to freeze thaw cycle test. On
subjecting to freeze thaw cycle 1st set of creams were not stable. The 1st set of creams were thick
and there was formation of lumps in the cream post freeze thaw test. The 2nd set of creams
containing MCSE 20, GMS and ≥3% of CSA50 or ≥3% of CSA70 were stable post freeze thaw
cycle. The composition of creams stable post freeze thaw cycle test is presented in Table 6.
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Table 6. The composition of stable creams post freeze thaw test.
Percentage (%)
F1

F2

F3

F4

F5

F6

F7

F8

F9

F10

Complex

57.0

57.0

57.0

57.0

57.0

57.0

57.0

57.0

57.0

57.0

Water

2.5

0.5

2.5

0.5

3.5

1.5

2.5

0.5

2.5

0.5

Glycerine

1.0

1.0

1.0

1.0

1.0

1.0

1.0

1.0

1.0

1.0

PG

20.0

20.0

20.0

20.0

20.0

20.0

20.0

20.0

20.0

20.0

Transcutol

5.0

5.0

5.0

5.0

5.0

5.0

5.0

5.0

5.0

5.0

OD

4.0

4.0

4.0

4.0

4.0

4.0

4.0

4.0

4.0

4.0

MCSE 20

3.0

4.0

3.0

4.0

3.0

4.0

3.0

4.0

3.0

4.0

GMS

3.0

4.0

3.0

4.0

3.0

4.0

3.0

4.0

3.0

4.0

CSA 50

4.0

4.0

3.0

3.0

0.0

0.0

0.0

0.0

2.0

2.0

CSA 70

0.0

0.0

0.0

0.0

3.0

3.0

3.0

3.0

2.0

2.0

Stearic acid

0.0

0.0

1.0

1.0

0.0

0.0

1.0

1.0

0.0

0.0

Dimethicone

0.5

0.5

0.5

0.5

0.5

0.5

0.5

0.5

0.5

0.5
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Ingredients

3.4.2 Measurement of cream pH
The pH of fresh creams and post-freeze thaw test creams were in range of 4.72 to 5.36 and
4.61 to 5.29 (Table 7) for fresh creams and post freeze thaw subjected creams, respectively. The
pH of post freeze thaw cream was slightly decreased (Table 7). However, the change in pH of the
creams were negligible and hence this test demonstrates there would be no effect on the solubility
of drug constituents due to pH change in cream post freeze thaw cycle.

Table 7. Cream pH of different formulations pre and post-freeze thaw test.

Formulation ID

Pre-Freeze thaw Test

Post-Freeze thaw Test

% Change in pH

pH (Mean ± SD) n=3

pH (Mean ± SD) n=3

(Mean)

F1

4.72 ± 0.22

4.61 ± 0.10

-2.25

F2

5.30 ± 0.19

5.11 ± 0.13

-3.56

F3

5.36 ± 0.23

5.18 ± 0.09

-3.34

F4

5.36 ± 0.12

5.27 ± 0.05

-1.75

F5

5.30 ± 0.05

5.15 ± 0.04

-2.71

F6

5.19 ± 0.12

5.18 ± 0.01

-0.16

F7

5.26 ± 0.05

5.12 ± 0.08

-0.40

F8

4.74 ± 0.08

4.76 ± 0.08

-4.61

F9

5.31 ± 0.04

5.29 ± 0.04

-2.49

F10

5.28 ± 0.07

5.04 ± 0.10

-2.57
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3.4.3 Globule Size determination
Increase in temperature decreases viscosity of creams leading to disruption of globules thus
formation of smaller size globules and make creams more susceptible to coalescence followed by
phase separation. Decrease in the temperature would lead to crystallization of components in
cream and leading to changes in size of globules. However, the effect of temperature on the creams
depends on nature of oil phase, solubility of drug and ratio of oil to water in O/W creams (82). The
globule size of creams which were stable at freeze thaw test was measured. The d10, d50 and d90
diameter were extrapolated from the cumulative frequency Vs globule size plot. Where, d10, d50
and d90 are diameters at which 10, 50 and 90% of globules is comprised of globule with lesser
diameter than d10, d50 and d90 values, respectively.
The globule size distribution of creams F3, F4, F7 and F8 was increased post freeze-thaw
cycle, however there was no change in globule size distribution of creams F1, F2, F5, F6, F9 and
F10 (Table 8). The d10, d50 and d90 of F3, F4, F7 and F8 were increased, this could be attributed
to the presence of stearic acid in these formulations. The change in globule size of F3, F4, F7 and
F8 creams demonstrates changes in the microstructure, which could adversely affect the stability
of formulation and permeation of the drugs incorporated in the creams.
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Table 8. The globule size distribution in O/W creams.
Globule Diameter (µm)
Formulation ID

Pre-Freeze thaw (µm)

Post-Freeze thaw (µm)

d10

d50

d90

d10

d50

d90

F1

1.41

2.37

4.33

1.27

2.9

6.01

F2

1.16

1.91

4.15

2.73

4.59

6.99

F3

1.15

1.82

4.01

1.23

2.45

6.03

F4

1.23

2.27

4.15

1.49

3.27

6.01

F5

1.37

3.07

5.57

1.32

2.98

6.53

F6

1.22

2.25

4.21

1.63

2.95

5.61

F7

1.14

1.84

4.39

1.93

3.43

6.13

F8

2.13

3.98

5.93

2.9

5.15

7.37

F9

1.31

2.36

3.43

1.33

2.62

6.17

F10

1.19

2.17

4.01

1.34

3.02

4.89

3.4.4 In vitro release testing of SBE--CD–silymarin creams
The SBE--CD–silymarin creams F1, F2, F5, F6, F9 and F10 with minimal changes in
globule size was tested for in vitro release. In vitro release test of topical dosage forms can be used
as a tool to assess the formulations potential to deliver drug consistently at the site of absorption.
The in vitro release rate can demonstrate the collective influence of various physical and chemical
properties like globule size, solubility and rheological properties of formulations (81).
In vitro release rate and profile of silymarin constituents from creams F1, F2, F5, F6, F9
and F10 are presented in Table 8 and Figure 5, respectively. The release study data demonstrates
in vitro release rates of silymarin constituents from formulations are in order of F2 < F1 < F10 <
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F9 < F5≈ F6 (Table 9). The lag phase for drug release were in order of F5=F6 < F9 < F10 < F2 <
F1. The decreased in vitro release rate and percentage drug release from F1, F2, F9 and F10
formulations can be attributed to viscosity of formulations, previous reported studies have
demonstrated CSA 50 increases the viscosity of formulations compared to CSA 70 containing
formulations (83).

Table 9. In vitro release rates of silymarin constituents from F1, F2, F5, F6, F9 and F10 creams.
In vitro Release Rate (µg/cm2/h) Mean ± SD (n=3)

Silymarin
Constituents
Taxifolin

F1

F2

F5

F6

F9

F10

0.85 ± 0.33 0.77 ± 0.02 5.84 ± 0.48 5.79 ± 0.72 2.85 ± 0.29 2.80 ± 0.31

Silychristin

1.25 ± 0.57 0.84 ± 0.10 22.9 ± 0.81 25.1 ± 2.46

Silydianin

2.16 ± 0.48 1.88 ± 0.15 22.1 ± 0.67 23.4 ± 1.39 9.52 ± 1.69 7.60 ± 0.93

Silybin A

5.27 ± 1.57 4.61 ± 0.24 64.6 ± 2.25 59.0 ± 13.2 27.8 ± 2.70 27.2 ± 1.77

Silybin B

8.05 ± 2.28 8.14 ± 0.24

127 ± 9.60

116 ± 31.1

8.00± 1.58

5.90 ± 0.87

54.3 ± 5.13 50.9 ± 6.31

Isosilybin A 5.02 ± 3.36 2.54 ± 0.24 42.5 ± 0.36 42.2 ± 4.95 19.4 ± 6.38 12.8 ± 3.65
Isosilybin B

0.95 ± 0.07 0.61 ± 0.03 10.6 ± 0.40 11.1 ± 0.30 3.82 ± 0.28 3.35 ± 0.57
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Figure 5. The in vitro release profile of taxifolin (A), silychristin (B), silydianin (C), silybin A (D), silybin (E), isosilybin (F)
and isosilybin (D) from F1, F2, F5, F6, F9 and F10 formulations.

3.4.5 In vitro permeation testing of SBE--CD–silymarin cream
The F5 and F6 creams with good release characteristics were evaluated for ex vivo human
cadaver skin penetration studies. The cumulative amount permeated, and amount of drug
penetrated human cadaver skin presented in Figure 5 and Figure 6.
The cumulative amount of TX, SC, SD, SA, SB, ISA and ISB permeated across the human
cadaver skin on application of F6 SBE--CD–silymarin cream was increased by 1.65, 1.78, 1.55,
1.45, 1.37, 1.39 and 1.49 compared to application of F5 SBE--CD-silymarin cream, respectively
(Figure 6). The amount of TX, SC, SD, SA, SB, ISA and ISB penetrated human cadaver skin on
application of F6 SBE--CD-silymarin cream was increased by 1.77, 1.16, 1.49, 1.30, 1.16, 0.91
and 1.63 compared to application of F5 SBE--CD-silymarin cream, respectively (Figure 5). The
increase in permeation and penetration of silymarin constituents on application of F6 creams can
be attributed to presence of 4% of surfactants (MCSE 20 and GMS), whereas F5 creams contains
3% of surfactants (MCSE 20 and GMS).
Based on above results the permeation and penetration of silymarin constituents on
application of F6 creams were evaluated at 6, 12, 18 and 24 h in human cadaver skin. The amount
of drug permeated across the skin and penetrated in to skin was increased with time (Figure 7).
The order of permeation and penetration of silymarin constituents was SD < TX < SB < ISB < ISA
< SB < SC and TX < SB < SD < ISB < ISA < SA at 24 h, respectively.
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Figure 6. Ex vivo human skin permeation and penetration of silymarin constituents on application
of F5 and F6 SBE--CD-silymarin topical formulation.
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Figure 7. Ex vivo human skin permeation and penetration of silymarin constituents on application
of SBE--CD-silymarin topical formulation (F6) at 6, 12, 18 and 24 h.
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3.5 SBE--CD-silymarin topical formulation stability
The stability of silymarin constituents in SBE-β-CD–silymarin cream under two sets of
conditions, 25 °C (60% RH) and 40 °C (75% RH), was ≥ 92.4 and ≥ 91.3% (Figure 8) for periods
3 months, respectively.
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Figure 8. Stability of the silymarin constituents in SBE-β-CD–silymarin cream at 25 °C (60% RH)
and 40 °C (75% RH) for periods of 3 months. Each point represents the mean ± SD of triplicate
values.
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4. Conclusion
The silymarin constituents have very low non-specific binding, this would have a
negligible effect on the permeation, and it will not affect the therapeutic action if adequate levels
of silymarin delivered. The in-vitro clearance study indicates that silymarin constituents have
longer elimination half- life in skin except SD and thus the therapeutic effects of silymarin on skin
would be prolonged on application as a topical formulation. An understanding of the capacity and
impact of drug biotransformation within skin and skin binding is an important component in
assessing pharmacotherapy directed to or through the cutaneous environment, which can be
modulated by standardizing dose for transdermal or topical drug delivery. Ex-vivo porcine
epidermis penetration studies demonstrated SBE-β-CD enhances the skin penetration of SC, SD,
SA, SB and ISA. The penetration enhancer screening demonstrated propylene glycol and
transcutol in SBE-β-CD–silymairn complex potentiates the skin penetration of all silymarin
constituents. SBE-β-CD–silymarin cream was developed and optimized to stabilize the cream and
increase the skin penetration and permeation of all silymarin constituents across the skin. The
developed SBE-β-CD–silymarin cream can be used for treatment of various skin ailments.
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sciences and pharmacy 2011; 2(1):58-74.
➢ Chandrashekar M Sultanpur, Deepa K, S.Vijay Kumar. Comprehensive review on HbA1c in
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Publication under Communication
➢ Vijay Kumar Shankar, Anitha Police, Pankaj Pandey, Zachary Cuny, Robert J. Doerksen, S.
Narasimha Murthy. Optimization of Sulfobutyl-Eher- β-Cyclodextrins Levels in Oral
Formulation to Enhance Progesterone Bioavailability.
➢ Vijay Kumar Shankar, Anitha Police, Pankaj Pandey, Zachary Cuny, Robert J. Doerksen, S.
Narasimha Murthy. Oral bioavailability enhancement of silymarin constituents using SBE-βCD.
➢ Anitha Police, Vijay Kumar Shankar, S. Narasimha Murthy. Role of Taurine Transporter in
Retinal Uptake of Vigabatrin.
➢ Anitha Police, Vijay Kumar Shankar, S. Narasimha Murthy. Cellular Mechanism of
Vigabatrin induced Retinal Neuronal and Epithelial Toxicity.
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Poster Presentations at Scientific Conferences
➢ PharmSci 360 Annual meeting 2018, Washington, DC.
• In-vitro Dermatokinetic of Silymarin in Human Skin Models.
• Influence of Sulfobutylether-β-Cyclodextrin on Intravenous Pharmacokinetics of
Silymarin.
• Optimization of Sulfobutyl-Ether- β-Cyclodextrin Levels in Oral Formulation to Increase
Bioavailability of Progesterone.
➢ AAPS Annual Convention and Meeting 2017, San Deigo, CA.
• Development of Captisol-Enabled™ Silymarin Topical Formulation.
• Effect of Cyclodextrin on Drug Plasma Protein Binding Kinetics.
• Method Development and Validation of Benzalkonium Chloride using LC-MS/MS.
• Tissue Distribution of Silymarin Constituents and their Metabolites in Rats on Oral
Administration of Silymarin Formulations.
➢ AAPS Annual Convention and Meeting 2016, Denver, CO.
• In-vitro Intestinal Permeability and Pharmacokinetic Studies of Captisol® Enabled
Silymarin Constituents.
➢ Metabolic Stability of Δ9-Tetrahydrocannabinol in Human Skin Model (iposter). NISBRE
meeting (Washington, DC) 2016 funded by an IDeA from the NIGMS of the NIH, USA.
➢ Progesterone (BCS Class II Model Drug) Solubility Enhancement by Modified βCyclodextrins complexation. AAPS Annual Convention and Meeting 2015, Orlando, FL.
➢ Influence of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of Gliclazide in
Rats and Rabbits. 61st Indian Pharmaceutical Congress 2009, India.
Volunteer Experience
➢ Reviewer for Drug Development and Industrial Pharmacy Journal Sep 2017 – present
➢ Reviewer for AAPS PharmSciTech Journal Sep 2018 – present
➢ Abstract screener for American Association of Pharmaceutical Scientists (AAPS) June 2017
– present.
➢ Graduate Teaching Assistant for Basic pharmaceutics at The University of Mississippi,
Department of Pharmaceutics and Drug delivery Jan – May 2017

143

